<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">TAH</journal-id>
<journal-id journal-id-type="hwp">sptah</journal-id>
<journal-title>Therapeutic Advances in Hematology</journal-title>
<issn pub-type="ppub">2040-6207</issn>
<issn pub-type="epub">2040-6215</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/2040620713489144</article-id>
<article-id pub-id-type="publisher-id">10.1177_2040620713489144</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Inherited predisposition to myeloproliferative neoplasms</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Jones</surname><given-names>Amy V.</given-names></name>
<aff id="aff1-2040620713489144">Wessex Regional Genetics Laboratory, Salisbury, UK, Faculty of Medicine, University of Southampton, Southampton, UK</aff>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Cross</surname><given-names>Nicholas C. P.</given-names></name>
<aff id="aff2-2040620713489144">Wessex Regional Genetics Laboratory, Salisbury NHS Foundation Trust, Salisbury SP2 8BJ, UK, Faculty of Medicine, University of Southampton, Southampton, UK</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-2040620713489144"><email>ncpc@soton.ac.uk</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2013</year>
</pub-date>
<volume>4</volume>
<issue>4</issue>
<fpage>237</fpage>
<lpage>253</lpage>
<permissions>
<copyright-statement>© The Author(s), 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Myeloproliferative neoplasms (MPNs) are haematological disorders characterized by an overproduction of mature myeloid cells with a tendency to transform to acute myeloid leukaemia. Clonal proliferation of myeloid progenitor cells is driven by somatically acquired mutations, most notably <italic>JAK2</italic> V617F, but there are important features relating to pathogenesis and phenotypic diversity that cannot be explained by acquired mutations alone. In this review we consider what is currently known about the role that inherited factors play in the development and biology of both sporadic and familial forms of MPN. Although most MPN cases appear to be sporadic, familial predisposition has been recognized for many years in a subset of cases and epidemiological studies have indicated the presence of common susceptibility alleles. Currently the <italic>JAK2</italic> 46/1 haplotype (also referred to as ‘GGCC’) is the strongest known predisposition factor for sporadic MPNs carrying a <italic>JAK2</italic> V617F mutation, explaining a large proportion of the heritability of this disorder. Less is known about what genetic variants predispose to MPNs that lack <italic>JAK2</italic> V617F, but there have been recent reports of interesting associations in biologically plausible candidates, and more loci are set to emerge with the application of systematic genome-wide association methodologies. Several highly penetrant predisposition variants that affect erythropoietin signalling, thrombopoietin signalling or oxygen sensing have been characterized in families with nonclonal hereditary erythrocytosis or thrombocytosis, but much less is known about familial predisposition to true clonal MPN. The heterogeneous pattern of inheritance and presumed genetic heterogeneity in these families makes analysis difficult, but whole exome or genome sequencing should provide novel insights into these elusive disorders.</p>
</abstract>
<kwd-group>
<kwd>Myeloproliferative neoplasms</kwd>
<kwd>familial myeloproliferative neoplasms</kwd>
<kwd>inherited predisposition</kwd>
<kwd><italic>JAK2</italic> 46/1 haplotype</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-2040620713489144" sec-type="intro">
<title>Introduction</title>
<p>Myeloproliferative neoplasms (MPNs) are a group of related haematological disorders characterized by an overproduction of mature blood cells and a tendency to transform to acute myeloid leukaemia [<xref ref-type="bibr" rid="bibr20-2040620713489144">Campbell and Green, 2006</xref>]. Although most cases appear to be sporadic, familial predisposition has been recognized for many years in a subset of cases and epidemiological studies have indicated the presence of common susceptibility alleles. This review discusses how inherited variants contribute to the development of both sporadic and familial forms of MPN.</p>
</sec>
<sec id="section2-2040620713489144">
<title>General features of MPNs</title>
<p>Classification of classical MPNs is based on which myeloid cell lineage is predominantly expanded in the peripheral blood, namely elevated red cell mass in polycythaemia vera (PV), and elevated platelet numbers in essential thrombocythaemia (ET). Primary myelofibrosis (PMF) patients display bone marrow fibrosis, a variable myeloid cell number, extramedullary haematopoiesis, and hepatosplenomegaly. Patients with PV and ET are at an increased risk of developing thrombotic or haemorrhagic events and may progress to an accelerated myelofibrosis phase. All three subtypes are associated with a long-term risk of transformation to acute myeloid leukaemia [<xref ref-type="bibr" rid="bibr144-2040620713489144">Vardiman <italic>et al.</italic> 2002</xref>]. The major presenting symptoms of MPN are related to hypertension or vascular abnormalities, however approximately half of all MPN patients are reported to be asymptomatic at diagnosis [<xref ref-type="bibr" rid="bibr139-2040620713489144">Tefferi and Vardiman, 2008</xref>]. PV and ET are diagnosed at a rate of 1 to 3 cases per 100,000 population per year, whereas PMF is rarer [<xref ref-type="bibr" rid="bibr62-2040620713489144">Johansson <italic>et al.</italic> 2004</xref>]. MPN is predominantly diagnosed in the age range of 50–60 years, although it can be diagnosed in younger individuals, particularly if there is a familial predisposition [<xref ref-type="bibr" rid="bibr16-2040620713489144">Bellanne-Chantelot <italic>et al.</italic> 2006</xref>]. A recent epidemiological study found life expectancy of all MPN subtypes is reduced when compared with the general population [<xref ref-type="bibr" rid="bibr58-2040620713489144">Hultcrantz <italic>et al.</italic> 2012</xref>] with PMF having the shortest survival rates [<xref ref-type="bibr" rid="bibr57-2040620713489144">Hoffman and Rondelli, 2007</xref>].</p>
</sec>
<sec id="section3-2040620713489144">
<title>Acquired mutations and cytogenetic abnormalities</title>
<p>Acquired somatic changes are well characterized in MPN, where clonal proliferation is driven by an increasingly diverse and somewhat complex set of genetic abnormalities [<xref ref-type="bibr" rid="bibr26-2040620713489144">Cross, 2011</xref>]. By far the most recurrent abnormality in MPN is <italic>JAK2</italic> V617F, a point mutation that activates the JAK2 cytoplasmic tyrosine kinase, deregulating downstream signalling pathways that drive myelopoiesis. <italic>JAK2</italic> V617F is found in approximately 95% of PV cases, and 50 to 60% of ET and PMF [<xref ref-type="bibr" rid="bibr15-2040620713489144">Baxter <italic>et al.</italic> 2005</xref>; <xref ref-type="bibr" rid="bibr61-2040620713489144">James <italic>et al.</italic> 2005</xref>; <xref ref-type="bibr" rid="bibr73-2040620713489144">Kralovics <italic>et al.</italic> 2005</xref>; <xref ref-type="bibr" rid="bibr84-2040620713489144">Levine <italic>et al.</italic> 2005</xref>]. One third of the remaining PV cases carry <italic>JAK2</italic> exon 12 mutations, often accompanied by an apparently isolated erythrocytosis [<xref ref-type="bibr" rid="bibr131-2040620713489144">Scott <italic>et al.</italic> 2007</xref>]. Unlike V617F where only a single codon is affected [<xref ref-type="bibr" rid="bibr32-2040620713489144">Dusa <italic>et al.</italic> 2008</xref>], there have been more than 40 different exon 12 mutations identified to date, most being complex insertion/deletion events affecting residues 536–547 [<xref ref-type="bibr" rid="bibr129-2040620713489144">Scott, 2011</xref>]. Approximately one third of <italic>JAK2</italic> V617F positive PV and PMF cases are homozygous with mutation burdens greater than 50%. This homozygosity generally occurs as a consequence of mitotic recombination of chromosome 9p, and is referred to as acquired uniparental disomy (UPD) or copy number neutral loss of heterozygosity (CNN-LOH) [<xref ref-type="bibr" rid="bibr15-2040620713489144">Baxter <italic>et al.</italic> 2005</xref>; <xref ref-type="bibr" rid="bibr61-2040620713489144">James <italic>et al.</italic> 2005</xref>; <xref ref-type="bibr" rid="bibr73-2040620713489144">Kralovics <italic>et al.</italic> 2005</xref>; <xref ref-type="bibr" rid="bibr84-2040620713489144">Levine <italic>et al.</italic> 2005</xref>]. In contrast, patients with ET have mutation levels predominantly in the heterozygous range of less than 50% [<xref ref-type="bibr" rid="bibr130-2040620713489144">Scott <italic>et al.</italic> 2006</xref>]. Other mutations are acquired in MPN at varying frequencies, but are all less common than <italic>JAK2</italic> V617F. These are listed in <xref ref-type="table" rid="table1-2040620713489144">Table 1</xref>, and include <italic>MPL</italic> [<xref ref-type="bibr" rid="bibr115-2040620713489144">Pikman <italic>et al.</italic> 2006</xref>], <italic>CBL</italic> [<xref ref-type="bibr" rid="bibr49-2040620713489144">Grand <italic>et al.</italic> 2009</xref>; <xref ref-type="bibr" rid="bibr126-2040620713489144">Sanada <italic>et al.</italic> 2009</xref>], <italic>TET2</italic> [<xref ref-type="bibr" rid="bibr29-2040620713489144">Delhommeau <italic>et al.</italic> 2009</xref>; <xref ref-type="bibr" rid="bibr80-2040620713489144">Langemeijer <italic>et al.</italic> 2009</xref>; <xref ref-type="bibr" rid="bibr138-2040620713489144">Tefferi <italic>et al.</italic> 2009</xref>], <italic>SH2B3</italic> [<xref ref-type="bibr" rid="bibr99-2040620713489144">Oh <italic>et al.</italic> 2010</xref>; <xref ref-type="bibr" rid="bibr105-2040620713489144">Pardanani <italic>et al.</italic> 2010a</xref>], <italic>ASXL1</italic> [<xref ref-type="bibr" rid="bibr21-2040620713489144">Carbuccia <italic>et al.</italic> 2009</xref>], <italic>EZH2</italic> [<xref ref-type="bibr" rid="bibr35-2040620713489144">Ernst <italic>et al.</italic> 2010</xref>; <xref ref-type="bibr" rid="bibr98-2040620713489144">Nikoloski <italic>et al.</italic> 2010</xref>], and <italic>DNMT3a</italic> [<xref ref-type="bibr" rid="bibr1-2040620713489144">Abdel-Wahab <italic>et al.</italic> 2011</xref>; <xref ref-type="bibr" rid="bibr135-2040620713489144">Stegelmann <italic>et al.</italic> 2011</xref>]. There are additional somatically acquired mutations associated with transformation to secondary acute leukaemia or disease progression, and this list of genes includes many that are also associated with <italic>de novo</italic> AML, such as <italic>TP53</italic> [<xref ref-type="bibr" rid="bibr53-2040620713489144">Harutyunyan <italic>et al.</italic> 2011b</xref>], <italic>RUNX1</italic> [<xref ref-type="bibr" rid="bibr31-2040620713489144">Ding <italic>et al.</italic> 2009</xref>; <xref ref-type="bibr" rid="bibr69-2040620713489144">Klampfl <italic>et al.</italic> 2011</xref>], <italic>NPM1</italic> [<xref ref-type="bibr" rid="bibr37-2040620713489144">Falini <italic>et al.</italic> 2005</xref>], <italic>FLT3, NRAS</italic> [<xref ref-type="bibr" rid="bibr12-2040620713489144">Bacher <italic>et al.</italic> 2007</xref>], <italic>IDH1/2</italic> [<xref ref-type="bibr" rid="bibr38-2040620713489144">Figueroa <italic>et al.</italic> 2010</xref>; <xref ref-type="bibr" rid="bibr50-2040620713489144">Green and Beer, 2010</xref>; <xref ref-type="bibr" rid="bibr136-2040620713489144">Tefferi <italic>et al.</italic> 2010a</xref>], <italic>IKZF1</italic> [<xref ref-type="bibr" rid="bibr60-2040620713489144">Jager <italic>et al.</italic> 2010</xref>], <italic>SF3B1</italic> [<xref ref-type="bibr" rid="bibr87-2040620713489144">Malcovati <italic>et al.</italic> 2011</xref>], and <italic>SRSF2</italic> [<xref ref-type="bibr" rid="bibr151-2040620713489144">Zhang <italic>et al.</italic> 2012a</xref>].</p>
<table-wrap id="table1-2040620713489144" position="float">
<label>Table 1.</label>
<caption>
<p>Acquired mutations characterized in sporadic MPN.</p>
</caption>
<graphic alternate-form-of="table1-2040620713489144" xlink:href="10.1177_2040620713489144-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Gene</th>
<th align="left">Mutation/location</th>
<th align="left">Genomic location</th>
<th align="left">Protein</th>
<th align="left" colspan="4">Frequency of mutation in sporadic MPN, % cases<hr/></th>
</tr>
<tr>
<th/>
<th/>
<th/>
<th/>
<th align="left">PV</th>
<th align="left">ET</th>
<th align="left">PMF</th>
<th align="left">Blast phase</th>
</tr>
</thead>
<tbody>
<tr>
<td><italic>JAK2</italic></td>
<td>V617F, exon 14</td>
<td>9p24</td>
<td>JAK2</td>
<td>95–97</td>
<td>50–60</td>
<td>50–60</td>
<td>50</td>
</tr>
<tr>
<td><italic>JAK2</italic></td>
<td>Various indels, exon 12</td>
<td>9p24</td>
<td>JAK2</td>
<td>1–2</td>
<td>rare</td>
<td>rare</td>
<td>NI</td>
</tr>
<tr>
<td><italic>MPL</italic></td>
<td>W515K/L/A, S505N, exon 10</td>
<td>1p34</td>
<td>TpoR</td>
<td>Rare</td>
<td>3–5</td>
<td>5–10</td>
<td>NI</td>
</tr>
<tr>
<td><italic>CBL</italic></td>
<td>Point mutations, exons 8 and 9</td>
<td>11q23</td>
<td>CBL</td>
<td>Rare</td>
<td>Rare</td>
<td>5–10</td>
<td>NI</td>
</tr>
<tr>
<td><italic>TET2</italic></td>
<td>Mutations across gene</td>
<td>4q24</td>
<td>TET2</td>
<td>10–20</td>
<td>5</td>
<td>10–20</td>
<td>20</td>
</tr>
<tr>
<td><italic>SH2B3</italic></td>
<td>Various mutations, mainly exon 2</td>
<td>12q24</td>
<td>LNK</td>
<td>1</td>
<td>3–6</td>
<td>3–6</td>
<td>10</td>
</tr>
<tr>
<td><italic>ASXL1</italic></td>
<td>Mutations across gene</td>
<td>20q11</td>
<td>ASXL1</td>
<td>2–5</td>
<td>2–5</td>
<td>13–20</td>
<td>20</td>
</tr>
<tr>
<td><italic>EZH2</italic></td>
<td>Various mutations across gene</td>
<td>7q36</td>
<td>EZH2</td>
<td>1–3</td>
<td>1</td>
<td>5–10</td>
<td>NI</td>
</tr>
<tr>
<td><italic>DNMT3a</italic></td>
<td>Mutations across gene</td>
<td>2p23</td>
<td>DNMT3a</td>
<td>5–10</td>
<td>1–5</td>
<td>5–10</td>
<td>20</td>
</tr>
<tr>
<td><italic>IDH1/IDH2</italic></td>
<td>Mainly <italic>IDH1</italic> R132 or <italic>IDH2</italic> R140</td>
<td>2q23/15q26</td>
<td>IDH1/2</td>
<td>Rare</td>
<td>Rare</td>
<td>6</td>
<td>20–36</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-2040620713489144">
<p>ET, essential thrombocythaemia; MPN, myeloproliferative neoplasm; PMF, primary myelofibrosis; PV, polycythaemia vera; NI, not investigated.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>A minority of MPNs display karyotypic abnormalities, the most recurrent being gain of part or all of chromosome 9 in PV, and this is associated with a copy number gain of <italic>JAK2</italic> V617F. Gain of chromosome 8, partial trisomy for 1q, and interstitial deletions of 13q and 20q have been recorded in all MPN subtypes. Acquired UPD 1p, 4q 7q, 9p, and 11q is usually associated with homozygosity for mutations in <italic>MPL, TET2, EZH2, JAK2</italic> and <italic>CBL</italic>, respectively [<xref ref-type="bibr" rid="bibr128-2040620713489144">Score and Cross, 2012</xref>]. However, the picture is incomplete as not all cases with acquired UPD in these regions have one of these corresponding mutations, and there are other, rarer regions of acquired UPD that have been detected in MPN for which mutations remain to be identified.</p>
<p>It is well accepted that chromosomal rearrangements and somatically acquired mutations drive clonal proliferation in MPNs, but much less is known about what factors contribute to the phenotype and severity of disease. The list of recurrent mutations isolated in MPN outlined in <xref ref-type="table" rid="table1-2040620713489144">Table 1</xref> is set to expand with new sequencing technologies, but bar a few exceptions (<italic>JAK2</italic> exon 12 mutations, for example) none of these mutations correlate tightly with haematologically defined disorders. Whilst the identification of phenotype-inducing mutations remains a possibility, it seems unlikely that specific somatically mutated genes or combinations of somatically mutated genes will fully explain the diversity of MPN, for example the reason why some individuals with <italic>JAK2</italic> V617F develop PV whereas other develop ET. An alternative possibility is that constitutional genetic variation drives much of the observed phenotypic heterogeneity between individuals.</p>
</sec>
<sec id="section4-2040620713489144">
<title>Genetic predisposition to MPN</title>
<p>As illustrated in <xref ref-type="fig" rid="fig1-2040620713489144">Figure 1</xref>, there are two main patterns of inherited predisposition to true, clonal MPN: (a) ‘true’ familial MPN with Mendelian inheritance, with the underlying risk alleles presumed to be rare and relatively highly penetrant; and (b) a more general predisposition, driven by weakly penetrant, common risk factors. In addition, mutations in several genes have been associated with hereditary erythrocytosis or thrombocytosis, disorders that are nonclonal which may occasionally be mistaken for true MPN. This review will discuss each of these in turn.</p>
<fig id="fig1-2040620713489144" position="float">
<label>Figure 1.</label>
<caption>
<p>Inherited predisposition to MPN and related disorders. Germline predisposition factors sit on a sliding scale of frequency and disease penetrance.</p>
</caption>
<graphic xlink:href="10.1177_2040620713489144-fig1.tif"/>
</fig>
</sec>
<sec id="section5-2040620713489144">
<title>Familial MPN</title>
<p>There are many reports in the literature of families with two or more members with MPN, and this clustering is an observation that exceeds that expected by chance in the general population. More detailed analysis of MPN pedigrees indicates the inheritance patterns are markedly heterogeneous, suggesting there are probably a variety of different germline mutations driving the predisposition. For many families, MPN is inherited in an autosomal dominant pattern [<xref ref-type="bibr" rid="bibr74-2040620713489144">Kralovics <italic>et al.</italic> 2003b</xref>; <xref ref-type="bibr" rid="bibr124-2040620713489144">Rumi <italic>et al.</italic> 2006</xref>], whereas for other families penetrance of disease is somewhat decreased, and some have a recessive pattern [<xref ref-type="bibr" rid="bibr122-2040620713489144">Rumi <italic>et al.</italic> 2007</xref>]. It has been suggested that the age of onset is lower in familial MPN compared with sporadic cases [<xref ref-type="bibr" rid="bibr16-2040620713489144">Bellanne-Chantelot <italic>et al.</italic> 2006</xref>; <xref ref-type="bibr" rid="bibr74-2040620713489144">Kralovics <italic>et al.</italic> 2003b</xref>], and there is some evidence for anticipation between generations [<xref ref-type="bibr" rid="bibr122-2040620713489144">Rumi <italic>et al.</italic> 2007</xref>]. As for clinical phenotype, approximately 60% of MPN families are characterized by individuals who all present with the same disease subtype, i.e. typically all PV or all ET whereas the remaining 40% of families have affected members with different diagnoses of MPN. Occasional families are characterized by individuals affected by more diverse myeloid malignancies including chronic myeloid leukaemia (CML) or systemic mastocytosis (SM) [<xref ref-type="bibr" rid="bibr16-2040620713489144">Bellanne-Chantelot <italic>et al.</italic> 2006</xref>]. There appears to be a stronger propensity for family members with PMF to transform to acute leukaemia [<xref ref-type="bibr" rid="bibr122-2040620713489144">Rumi <italic>et al.</italic> 2007</xref>].</p>
<p>Whatever the driving factor, the majority of familial MPN cases have a disease that closely mirrors that of sporadic MPN, with similar clinical features and thrombotic and haemorrhagic complications, and risk of progression to myelofibrosis and leukaemia. Moreover, it has been shown that haematopoietic progenitors from select cases of familial MPN were clonal and were able to form erythropoietin-independent erythroid colonies <italic>in vitro</italic>, a hallmark of sporadic PV and a feature not observed in healthy individuals or cases with idiopathic erythrocytosis [<xref ref-type="bibr" rid="bibr72-2040620713489144">Kralovics <italic>et al.</italic> 2003a</xref>]. It has been estimated that as many as 5–10% of sporadic MPNs actually have a family history, a measure that has become more easily defined now there are common molecular markers for discriminating MPN from other hereditary conditions. Affected family members with MPN carry mutations associated with sporadic MPN, but the vast majority of these are not inherited. The genetic basis for this familial clustering is not yet known despite several linkage studies attempting to identify candidate regions [<xref ref-type="bibr" rid="bibr16-2040620713489144">Bellanne-Chantelot <italic>et al.</italic> 2006</xref>]. The task of locating abnormalities is likely to have been hampered by the fact that MPNs are late-onset diseases, penetrance appears to be variable and there be a considerable diversity of predisposition loci [<xref ref-type="bibr" rid="bibr122-2040620713489144">Rumi <italic>et al.</italic> 2007</xref>]. Whatever these inherited genetic factors turn out to be, they cannot be the sole cause of clonal proliferation because development of MPN requires the acquisition of additional somatic mutations. It is tempting to hypothesize this factor could contribute to increased genomic instability at the level of DNA replication or DNA repair in response to DNA damaging agents or replication stress of immunologically challenged stem cells, perhaps resulting in a weaker predisposition than that seen with inherited mutations in true tumour suppressor genes or DNA repair proteins [<xref ref-type="bibr" rid="bibr11-2040620713489144">Assumpcao <italic>et al.</italic> 2008</xref>; <xref ref-type="bibr" rid="bibr91-2040620713489144">Meindl <italic>et al.</italic> 2010</xref>].</p>
<p>To date, <italic>JAK2</italic> V617F together with <italic>MPL</italic> W515L/K and inactivating <italic>TET2</italic> mutations remain the most recurrently acquired mutations in both sporadic and familial MPN [<xref ref-type="bibr" rid="bibr125-2040620713489144">Saint-Martin <italic>et al.</italic> 2009</xref>]. <italic>JAK2</italic> V617F has never been reported to be inherited through the germline but other weaker activating alleles appear to be responsible for occasional families with hereditary thrombocytosis (see below). Similarly, <italic>MPL</italic> W515L/K is not inherited but other alleles may pass through the germline and again be associated with hereditary thrombocytosis. <italic>TET2</italic> mutations are generally acquired, but a single family has been described with an inherited truncating mutation that may have predisposed to true clonal MPN [<xref ref-type="bibr" rid="bibr127-2040620713489144">Schaub <italic>et al.</italic> 2010</xref>].</p>
</sec>
<sec id="section6-2040620713489144">
<title>Common variation and the <italic>JAK2</italic> 46/1 haplotype</title>
<p>One of the main lines of evidence for the presence of common susceptibility genes in the general population comes from an important Swedish epidemiological study which revealed a fivefold to sevenfold increased relative risk (RR) of developing MPN among first-degree relatives of MPN patients. This risk increases to 12 fold when comparing the risk of ET in first-degree relatives of ET patients [<xref ref-type="bibr" rid="bibr79-2040620713489144">Landgren <italic>et al.</italic> 2008</xref>]. In humans, evidence that inherited single nucleotide polymorphisms (SNPs) contribute to MPN development was first suggested by Pardanani and colleagues, who linked SNPs within the <italic>JAK2</italic> and <italic>EpoR</italic> genes with specific MPN subtypes [<xref ref-type="bibr" rid="bibr104-2040620713489144">Pardanani <italic>et al.</italic> 2008</xref>].</p>
<p>Subsequently the unexpected finding was made that the <italic>JAK2</italic> V617F mutation does not arise randomly, but rather preferentially appears on a particular haplotype of <italic>JAK2</italic> referred to as ‘46/1’ [<xref ref-type="bibr" rid="bibr64-2040620713489144">Jones <italic>et al.</italic> 2009</xref>] or ‘GGCC’ [<xref ref-type="bibr" rid="bibr101-2040620713489144">Olcaydu <italic>et al.</italic> 2009a</xref>]. This haplotype is seen at a frequency of 24% in European populations, meaning that roughly 50% of individuals carry at least one allele [<xref ref-type="bibr" rid="bibr64-2040620713489144">Jones <italic>et al.</italic> 2009</xref>; <xref ref-type="bibr" rid="bibr67-2040620713489144">Kilpivaara <italic>et al.</italic> 2009</xref>; <xref ref-type="bibr" rid="bibr101-2040620713489144">Olcaydu <italic>et al.</italic> 2009a</xref>]. The single 46/1 locus accounts for an estimated 50% of the population attributable risk of developing an MPN, that is the proportion of the risk of developing MPN conferred by inherited factors. Moreover, <italic>JAK2</italic> 46/1 is one of the strongest predisposition factors linked to development of a molecularly defined malignancy identified to date with an odds ratio of developing MPN being threefold to fourfold higher in patients carrying a 46/1 allele compared with noncarriers. Although 46/1 is likely to be the most important common risk factor for MPN development, its penetrance is very low and it cannot be used to predict disease development. Furthermore, the <italic>JAK2</italic> 46/1 haplotype does not explain familial MPNs [<xref ref-type="bibr" rid="bibr103-2040620713489144">Olcaydu <italic>et al.</italic> 2011</xref>] or the phenotypic diversity associated with <italic>JAK2</italic> V617F. Recent reports have confirmed the association between 46/1 and MPN in Japanese [<xref ref-type="bibr" rid="bibr100-2040620713489144">Ohyashiki <italic>et al.</italic> 2012</xref>] and Chinese cases [<xref ref-type="bibr" rid="bibr152-2040620713489144">Zhang <italic>et al.</italic> 2012b</xref>], indicating that the underlying mechanism is not limited to Caucasians and must therefore have a relatively old evolutionary basis.</p>
<p>Patients with normal karyotype acute myeloid leukaemia (NK-AML) have an excess of <italic>JAK2</italic> 46/1, and the data indicated a trend towards shorter survival and myelomonocytic proliferation [<xref ref-type="bibr" rid="bibr9-2040620713489144">Andrikovics <italic>et al.</italic> 2010</xref>; <xref ref-type="bibr" rid="bibr93-2040620713489144">Nahajevszky <italic>et al.</italic> 2011</xref>]. This is an interesting finding especially in the context of a recent population-based investigation into risk of myeloid and lymphoid diseases in first-degree relatives of adults with AML and myelodysplastic syndrome (MDS). For AML patients over the age of 21, the most significant risk in relatives was for PV (RR 2.3), suggesting that shared predisposition alleles predispose more broadly to myeloid malignancy, and that <italic>JAK2</italic> 46/1 may prove a good candidate locus in this situation [<xref ref-type="bibr" rid="bibr47-2040620713489144">Goldin <italic>et al.</italic> 2012</xref>]. The association of 46/1 with a wider series of haematological disorders suggests the biological consequence(s) of this single predisposition locus could manifest in a wider range haematopoietic cell types and contribute more broadly to the pathogenesis of leukaemia.</p>
</sec>
<sec id="section7-2040620713489144">
<title>Underlying reasons for the association between 46/1 and MPN</title>
<p>It is not clear why acquisition of <italic>JAK2</italic> V617F is associated with a particular inherited background. The 46/1 haplotype spans 180–220kb and is made up of hundreds of SNPs in tight linkage disequilibrium (LD). Several SNPs have been used to define or tag 46/1 but these are simply markers and the true causal variant(s) could be anywhere in the LD block and may even be further away. The block contains the whole or most of the <italic>JAK2</italic> gene plus <italic>INSL4</italic> and <italic>INSL6</italic>, two genes that are not believed to be expressed in haematopoietic cells. It seems highly likely therefore that the underlying variant(s) in some way influence <italic>JAK2</italic>, although it is possible that there could be long-range effects on other genes.</p>
<p>Two broad hypotheses have been suggested to explain the observed association. The first, termed ‘hypermutability’ considers 46/1 as more genetically unstable, acquiring V617F at a faster rate than other haplotypes. In the second, called ‘fertile ground’, V617F is suggested to arise on all haplotypes at an equal rate, but there is an additional factor on 46/1 which provides a selective advantage to the V617F-positive clone. Support for the hypermutability hypothesis comes from the observation that V617F has apparently arisen at least twice in some individuals [<xref ref-type="bibr" rid="bibr78-2040620713489144">Lambert <italic>et al.</italic> 2009</xref>; <xref ref-type="bibr" rid="bibr101-2040620713489144">Olcaydu <italic>et al.</italic> 2009a</xref>], and possibly by the fact that <italic>JAK2</italic> exon 12 mutations are also associated with 46/1, albeit with a weaker risk [odds ratio (OR) 1.81–2.10] [<xref ref-type="bibr" rid="bibr63-2040620713489144">Jones <italic>et al.</italic> 2010</xref>; <xref ref-type="bibr" rid="bibr102-2040620713489144">Olcaydu <italic>et al.</italic> 2009b</xref>]. There are also reports of isolated cases which carry biclonal <italic>JAK2</italic> V617F and exon 12 mutations [<xref ref-type="bibr" rid="bibr85-2040620713489144">Li <italic>et al.</italic> 2008</xref>], a finding that appears to be highly improbable given the low incidence of MPN. Although this might be explained by a genetically unstable <italic>JAK2</italic> haplotype, it is also possible that such individuals have an inherited or acquired propensity to acquire further mutations, not only in <italic>JAK2</italic> but also in other genes as well. Indeed several cases that are positive for both <italic>JAK2</italic> V617F and <italic>BCR-ABL</italic> or <italic>MPL</italic> 515 mutations have been reported [<xref ref-type="bibr" rid="bibr59-2040620713489144">Hussein <italic>et al.</italic> 2007</xref>; <xref ref-type="bibr" rid="bibr81-2040620713489144">Lasho <italic>et al.</italic> 2006</xref>] which lends support to the notion of a general hypermutability that is independent of 46/1.</p>
<p>We have argued that the finding that <italic>JAK2</italic> 46/1 is also associated with <italic>JAK2</italic> V617F-negative MPNs (albeit more weakly; OR 1.24) [<xref ref-type="bibr" rid="bibr63-2040620713489144">Jones <italic>et al.</italic> 2010</xref>; <xref ref-type="bibr" rid="bibr106-2040620713489144">Pardanani <italic>et al.</italic> 2010b</xref>; <xref ref-type="bibr" rid="bibr137-2040620713489144">Tefferi <italic>et al.</italic> 2010b</xref>], as well as MPNs that are V617F-negative but carry the <italic>MPL</italic> W515 mutations (OR 1.44) [<xref ref-type="bibr" rid="bibr63-2040620713489144">Jones <italic>et al.</italic> 2010</xref>], is more in keeping with the idea that there is some functional difference on 46/1 that contributes to disease development. Other, much smaller, studies however have not confirmed the association between 46/1 and <italic>MPL</italic> mutated MPN and further studies are needed to define their relationship [<xref ref-type="bibr" rid="bibr114-2040620713489144">Pietra <italic>et al.</italic> 2012</xref>; <xref ref-type="bibr" rid="bibr137-2040620713489144">Tefferi <italic>et al.</italic> 2010b</xref>].</p>
<p>If <italic>JAK2</italic> on the 46/1 haplotype is functionally different, it might be expected to influence clinical phenotype of MPN. This is currently a matter of debate, with some studies failing to find any link to clinical parameters [<xref ref-type="bibr" rid="bibr51-2040620713489144">Guglielmelli <italic>et al.</italic> 2010</xref>; <xref ref-type="bibr" rid="bibr63-2040620713489144">Jones <italic>et al.</italic> 2010</xref>; <xref ref-type="bibr" rid="bibr71-2040620713489144">Kouroupi <italic>et al.</italic> 2011</xref>; <xref ref-type="bibr" rid="bibr106-2040620713489144">Pardanani <italic>et al.</italic> 2010b</xref>], and others providing interesting correlations with 46/1. One study has shown that the absence of 46/1 is linked to inferior survival in PMF [<xref ref-type="bibr" rid="bibr137-2040620713489144">Tefferi <italic>et al.</italic> 2010b</xref>], but this remains unsubstantiated [<xref ref-type="bibr" rid="bibr51-2040620713489144">Guglielmelli <italic>et al.</italic> 2010</xref>]. It has been reported that in untreated PV patients with homozygous 46/1, the V617F allele burden is more likely to progressively increase over a year when compared to PV cases that did not have any 46/1 alleles, suggesting 46/1 might facilitate greater expansion of V617F homozygous clones [<xref ref-type="bibr" rid="bibr6-2040620713489144">Alvarez-Larran <italic>et al.</italic> 2012</xref>]. A recent study in Chinese MPNs revealed 46/1 is associated with platelet count in PV and PMF, and raised haemoglobin and haematocrit in ET [<xref ref-type="bibr" rid="bibr147-2040620713489144">Wang <italic>et al.</italic> 2013</xref>]. A significant excess of 46/1 alleles has been reported in <italic>JAK2</italic> V617F-positive splanchnic vein thrombosis (SVT) patients, and the presence of 46/1 has been correlated with increased erythropoiesis in <italic>JAK2</italic> V617F negative cases with SVT [<xref ref-type="bibr" rid="bibr134-2040620713489144">Smalberg <italic>et al.</italic> 2011</xref>]. It might also be expected that 46/1 could influence blood counts in normal individuals. Indeed one study involving approximately 50,000 Danish individuals correlated the presence of 46/1 alone with an elevation in erythrocyte count, and reduction in platelet count [<xref ref-type="bibr" rid="bibr96-2040620713489144">Nielsen <italic>et al.</italic> 2013</xref>]. However no such associations were detected in similarly sized genome-wide association studies (GWASs) [<xref ref-type="bibr" rid="bibr45-2040620713489144">Gieger <italic>et al.</italic> 2011</xref>; <xref ref-type="bibr" rid="bibr95-2040620713489144">Newton-Cheh <italic>et al.</italic> 2009</xref>; <xref ref-type="bibr" rid="bibr142-2040620713489144">van der Harst <italic>et al.</italic> 2012</xref>].</p>
<p>Other support favouring the fertile ground hypothesis comes from the association of 46/1 with haematopoietic colony numbers in normal individuals [<xref ref-type="bibr" rid="bibr64-2040620713489144">Jones <italic>et al.</italic> 2009</xref>] and, more convincingly, a 46/1 tag SNP having robust association with inflammatory disorders, such as Crohn’s disease [<xref ref-type="bibr" rid="bibr14-2040620713489144">Barrett <italic>et al.</italic> 2008</xref>], ulcerative colitis [<xref ref-type="bibr" rid="bibr7-2040620713489144">Anderson <italic>et al.</italic> 2011a</xref>], and psoriasis [<xref ref-type="bibr" rid="bibr34-2040620713489144">Ellinghaus <italic>et al.</italic> 2012</xref>]. Indeed, epidemiological studies have shown MPN patients are at a greater risk of developing a range of autoimmune/auto inflammatory diseases before or after onset of MPN [<xref ref-type="bibr" rid="bibr13-2040620713489144">Barosi <italic>et al.</italic> 2010</xref>; <xref ref-type="bibr" rid="bibr75-2040620713489144">Kristinsson <italic>et al.</italic> 2010</xref>; <xref ref-type="bibr" rid="bibr120-2040620713489144">Rondeau <italic>et al.</italic> 1983</xref>]. GWASs in Crohn’s disease and ulcerative colitis have also revealed significant associations with the IL-23 receptor, IL12B, TYK2, and STAT3, suggesting whole signalling pathways centred around JAK2 could be functionally different and collectively contribute to the pathogenesis of these disorders [<xref ref-type="bibr" rid="bibr83-2040620713489144">Lees <italic>et al.</italic> 2011</xref>]. So far there has been no evidence for other shared risk factors between MPN and autoimmune disorders apart from 46/1. Given the importance of JAK-STAT signalling in MPN, the Crohn’s associated STAT3 variant was investigated in MPN but not found to be significantly different from controls [<xref ref-type="bibr" rid="bibr65-2040620713489144">Jones and Cross, 2010</xref>]. More systematic searches are required to determine if there are other shared genetic susceptibility factors between MPNs and immune-related disorders.</p>
<p>Despite these considerations, the biological mechanism behind the association of the 46/1 haplotype and acquisition of <italic>JAK2</italic> and other mutations remains uncharacterized. The finding that there were no sequence changes on the 46/1 allele, and no <italic>JAK2</italic> expression changes detected in peripheral blood leukocytes suggests that if there is a functional variant, its effects are subtle and perhaps restricted to a particular haematopoietic progenitor cell. A small functional effect would also be consistent with the observation that 46/1 is not required for disease development, as V617F arises on a different haplotype in approximately 25% of <italic>JAK2</italic> mutated MPNs. It is also possible that the hypermutability and fertile ground hypotheses are not mutually exclusive and elements of both may be important. Finally, the hypothesis that there is a single causal variant on 46/1 may not be correct and it may turn out that different underlying variants may be driving different associations.</p>
</sec>
<sec id="section8-2040620713489144">
<title>The phenotypic diversity of MPN</title>
<p>One of the most interesting unsolved questions in MPN relates to understanding what factors drive the phenotypic diversity associated with particular mutations. In some instances it appears that particular mutations are strongly associated with clinical phenotype. <italic>JAK2</italic> exon 12 mutations have only been detected in cases with V617F negative PV and idiopathic erythrocytosis [<xref ref-type="bibr" rid="bibr111-2040620713489144">Percy <italic>et al.</italic> 2007b</xref>; <xref ref-type="bibr" rid="bibr131-2040620713489144">Scott <italic>et al.</italic> 2007</xref>]. Mutations at <italic>JAK2</italic> R683 are seen in a small proportion of children with acute lymphoblastic leukaemia [<xref ref-type="bibr" rid="bibr18-2040620713489144">Bercovich <italic>et al.</italic> 2008</xref>; <xref ref-type="bibr" rid="bibr66-2040620713489144">Kearney <italic>et al.</italic> 2009</xref>], and the presence of <italic>JAK2</italic> R683 mutations correlated with aberrant expression of <italic>CRLF2</italic>, a cytokine receptor that signals through JAK2 [<xref ref-type="bibr" rid="bibr55-2040620713489144">Hertzberg <italic>et al.</italic> 2010</xref>]. Mutations in <italic>MPL</italic> W515 have only been detected in ET and PMF [<xref ref-type="bibr" rid="bibr115-2040620713489144">Pikman <italic>et al.</italic> 2006</xref>]. Further afield, atypical MPNs such as SM are characterized by mutations in the stem cell factor receptor gene (<italic>KIT</italic> D816V) [<xref ref-type="bibr" rid="bibr40-2040620713489144">Furitsu <italic>et al.</italic> 1993</xref>], and <italic>FIP1L1-PDGFRA</italic> is usually restricted to cases with hypereosinophilic syndrome [<xref ref-type="bibr" rid="bibr25-2040620713489144">Cools <italic>et al.</italic> 2003</xref>]. Other gene fusions, such as those involving <italic>FGFR1</italic>, also show marked phenotypic correlations [<xref ref-type="bibr" rid="bibr2-2040620713489144">Aguiar <italic>et al.</italic> 1997</xref>; <xref ref-type="bibr" rid="bibr27-2040620713489144">Cross and Reiter, 2008</xref>]. Very recently, <italic>SETBP1</italic> mutations have been associated with atypical CML [<xref ref-type="bibr" rid="bibr113-2040620713489144">Piazza <italic>et al.</italic> 2012</xref>]. Current evidence shows a heterogeneous combination of mutations can be acquired in each MPN patient, and data is emerging to suggest that the order of acquisition of mutation may be important. However, it is likely that inherited factors also play an important role in determining phenotype.</p>
<p>The question why do some <italic>JAK2</italic> V617F patients develop PV whereas others develop ET remains unanswered. Homozygosity for V617F is more common in PV compared with ET, leading to the suggestion that increased <italic>JAK2</italic> V617F signalling is associated with a more erythrocytic phenotype [<xref ref-type="bibr" rid="bibr15-2040620713489144">Baxter <italic>et al.</italic> 2005</xref>; <xref ref-type="bibr" rid="bibr61-2040620713489144">James <italic>et al.</italic> 2005</xref>; <xref ref-type="bibr" rid="bibr73-2040620713489144">Kralovics <italic>et al.</italic> 2005</xref>; <xref ref-type="bibr" rid="bibr84-2040620713489144">Levine <italic>et al.</italic> 2005</xref>]. This suggestion has some support from transgenic mouse models [<xref ref-type="bibr" rid="bibr141-2040620713489144">Tiedt <italic>et al.</italic> 2008</xref>] and also the fact that <italic>JAK2</italic> exon 12 mutations are more strongly activating that V617F. However, the strength of JAK2 signalling cannot be the whole story since many PV patients only carry heterozygous clones [<xref ref-type="bibr" rid="bibr130-2040620713489144">Scott <italic>et al.</italic> 2006</xref>]. Moreover, small homozygous V617F positive clones have been detected at low frequency in a substantial proportion of ET patients, but they appear to be constrained from expanding or they have no selective advantage [<xref ref-type="bibr" rid="bibr46-2040620713489144">Godfrey <italic>et al.</italic> 2012</xref>]. A qualitative difference in the signalling state of STAT proteins has been described in MPN; ET progenitors had high phosphorylation levels of STAT1 and STAT5, whereas PV progenitors had only phosphorylated STAT5 [<xref ref-type="bibr" rid="bibr24-2040620713489144">Chen <italic>et al.</italic> 2010</xref>]. The reasons behind this and other phenotypic differences are unclear, but are potentially the result of a complex interplay between acquired and/or inherited variation, and possibly environmental exposure, all unique to each MPN patient.</p>
<p>Other evidence that the genetic background may influence MPN phenotype comes from mouse models expressing <italic>JAK2</italic> V617F, where disease phenotype varies between mouse strains. When the <italic>JAK2</italic> V617F transgene was expressed in the BM of C57Bl/6 mice, the animals displayed erythrocytosis with mild leukocytosis. However when <italic>JAK2</italic> V617F was expressed in Balb/c mice, a different genetic background, the mice displayed erythrocytosis with dramatically increased leukocyte count and bone marrow fibrosis [<xref ref-type="bibr" rid="bibr76-2040620713489144">Lacout <italic>et al.</italic> 2006</xref>; <xref ref-type="bibr" rid="bibr148-2040620713489144">Wernig <italic>et al.</italic> 2006</xref>; <xref ref-type="bibr" rid="bibr150-2040620713489144">Zaleskas <italic>et al.</italic> 2006</xref>].</p>
</sec>
<sec id="section9-2040620713489144">
<title>Other predisposition factors in MPN</title>
<p>Whilst <italic>JAK2</italic> 46/1 accounts for a large component of the inherited risk for developing <italic>JAK2</italic> V617F positive MPN [<xref ref-type="bibr" rid="bibr79-2040620713489144">Landgren <italic>et al.</italic> 2008</xref>], it explains only a very minor component of <italic>JAK2</italic> V617F negative disease, suggesting that there may be other genetic risk variants. Recently, some reports of other common predisposition alleles linked to MPN have begun to emerge. Like <italic>JAK2</italic> 46/1, these loci were largely discovered using candidate gene approaches rather than systematic screens.</p>
<p>By focusing on genes involved in relevant signalling pathways, an excess of the glucocorticoid receptor β (<italic>GRβ</italic>) SNP A3669G (rs6198) was recently identified in PV but not ET cases. Expression of higher levels of a dominant negative isoform of GRβ appears to block stimulation by glucocorticoids and contribute to increased erythrocytosis [<xref ref-type="bibr" rid="bibr145-2040620713489144">Varricchio <italic>et al.</italic> 2011</xref>]. The A3669G variant has also been associated with blastic transformation in <italic>JAK2</italic> V617F positive PMF (OR of between 1.6 and 1.8), where the presence of the risk allele G/G correlated with a higher leukocyte count at diagnosis, splenomegaly, and higher numbers of circulating CD34+ cells [<xref ref-type="bibr" rid="bibr117-2040620713489144">Poletto <italic>et al.</italic> 2012</xref>]. In another study, common polymorphisms in DNA damage repair pathway genes were investigated for their contribution to transformation of ET and PV to acute leukaemia. In the <italic>ERCC2</italic> (<italic>XPD</italic>) gene the K751Q (rs13181) minor allele was statistically associated with both leukaemic transformation (OR 4.9) and development of nonmyeloid malignancies (OR 4.2). This significance remained even after controlling for the type of treatment that the patients received, as it has been suggested carriers of this risk allele might be more susceptible to the leukaemogenic effects of long-term exposure to particular therapies [<xref ref-type="bibr" rid="bibr54-2040620713489144">Hernandez-Boluda <italic>et al.</italic> 2012</xref>].</p>
<p>Following on from the observation that <italic>IDH</italic>-mutated glioblastomas are significantly enriched for risk variants in <italic>CCDC26</italic>, these polymorphisms were screened in a series of acute and chronic myeloid malignancies that also carry <italic>IDH</italic> mutations. Despite small numbers, modest associations with variants in <italic>CCDC26</italic> were observed between cases that carried particular <italic>IDH</italic> mutations <italic>versus IDH-</italic>unmutated counterparts [<xref ref-type="bibr" rid="bibr82-2040620713489144">Lasho <italic>et al.</italic> 2012</xref>]. Very recently, a small GWAS identified MPN-predisposition variants in the <italic>TERT</italic> gene which encodes a telomerase reverse transcriptase, and a weaker association in the ataxia telangiectasia mutated gene, <italic>ATM.</italic> These associations were independent of <italic>JAK2</italic> V617F status, and were made in a collection of different MPNs recruited in a web-based study where patients self-reported their diagnosis as being ET, PV, PMF, SM, or CML [<xref ref-type="bibr" rid="bibr56-2040620713489144">Hinds <italic>et al.</italic> 2012</xref>]. Lastly, an isolated case of PV who developed anaemia and later transformed to acute leukaemia was found to have acquired UPD on chromosome 14q. On further investigation, an inherited heterozygous nonsense mutation in the Fanconi anaemia complementation group M (<italic>FANCM</italic>) gene, located at 14q, was found to be reduced to homozygosity [<xref ref-type="bibr" rid="bibr52-2040620713489144">Harutyunyan <italic>et al.</italic> 2011a</xref>]. Whether this directly contributed to development of anaemia is unclear but no other candidate mutations were identified.</p>
<p>In an attempt to map out common predisposition factors more systematically, we are currently undertaking a GWAS to identify common SNPs with frequencies that differ significantly between unrelated Caucasian <italic>JAK2</italic> V617F negative MPN patients and ethnically matched healthy controls. This is a powerful approach for identifying disease-associated regions with no prior hypothesis, as the SNPs genotyped in both groups tag a large proportion of common genetic variation across the genome. Preliminary results indicate there are no disease associations as strong as that seen for <italic>JAK2</italic> 46/1, which is perhaps not surprising given the heterogeneous nature of <italic>JAK2</italic> V617F negative MPN, but some more modest associations are emerging close to interesting candidate genes.</p>
<p>Finally, there is mounting evidence to suggest inherited factors may have a broader effect on susceptibility to developing malignancy, as epidemiological studies have shown MPN patients are at a greater risk of developing both haematological and nonhaematological cancers. MPN patients have a 2.8- to 5.5-fold increased risk of developing a lymphoid neoplasm [<xref ref-type="bibr" rid="bibr123-2040620713489144">Rumi <italic>et al.</italic> 2011</xref>; <xref ref-type="bibr" rid="bibr143-2040620713489144">Vannucchi <italic>et al.</italic> 2009</xref>]. Patients with ET, PV and CML are at slightly increased odds of developing nonhaematological cancers, in the range of 1.2- to 1.6-fold [<xref ref-type="bibr" rid="bibr39-2040620713489144">Frederiksen <italic>et al.</italic> 2011</xref>]. These associations could in part be accounted for by prior leukaemogenic treatments which promote further malignancy, or for other haematological malignancies possibly the presence of V617F itself, which has been linked to increased risk of secondary cancer and DNA damage [<xref ref-type="bibr" rid="bibr97-2040620713489144">Nielsen <italic>et al.</italic> 2011</xref>; <xref ref-type="bibr" rid="bibr116-2040620713489144">Plo <italic>et al.</italic> 2008</xref>]. It has been reported that there is a modest increased incidence of PV in people of Jewish ancestry (5.8% <italic>versus</italic> 3%) in the French population [<xref ref-type="bibr" rid="bibr94-2040620713489144">Najean <italic>et al.</italic> 1998</xref>]. More strikingly, the incidence of MPN was tenfold higher in Ashkenazi Jews compared with other populations in Northern Israel [<xref ref-type="bibr" rid="bibr23-2040620713489144">Chaiter <italic>et al.</italic> 1992</xref>], suggesting MPN predisposition alleles might cluster in particular groups of individuals.</p>
</sec>
<sec id="section10-2040620713489144">
<title>Hereditary erythrocytosis and thrombocytosis</title>
<p>In other hereditary myeloproliferative disorders, the causative mutation typically segregates with all affected family members, and only one lineage predominates in a polyclonal fashion. Being nonneoplastic, affected individuals are highly unlikely to progress to more aggressive disease. Most often referred to as hereditary erythrocytosis [<xref ref-type="bibr" rid="bibr48-2040620713489144">Gordeuk <italic>et al.</italic> 2005</xref>], or hereditary thrombocytosis, several causative mutations have been well characterized and either target important components of cytokine signalling pathways or components of oxygen sensing pathways. These disorders have been classified into four groups (ECYT1-4) by Online Mendelian Inheritance in Man (OMIM), and have been reviewed extensively elsewhere [<xref ref-type="bibr" rid="bibr89-2040620713489144">McMullin, 2010</xref>; <xref ref-type="bibr" rid="bibr133-2040620713489144">Skoda, 2010</xref>], but we include a brief description here as occasional cases may be confused with true MPN.</p>
<p>Erythropoietin receptor (<italic>EPOR</italic>) mutations have been described in cases of hereditary erythrocytosis, primary familial and congenital PVs (PFCPs). Here, erythrocytosis is driven by a truncated EPOR protein, rendering progenitor cells hypersensitive to stimulation by erythropoietin (EPO), which is present at low levels in circulating serum. All <italic>EPOR</italic> mutations identified to date truncate the cytoplasmic domain of the EPOR protein, resulting in loss of a negative regulatory region at the C-terminus. PFCP patients are more likely to suffer from thrombotic and haemorrhagic events, and premature morbidity and mortality have been reported [<xref ref-type="bibr" rid="bibr4-2040620713489144">Al-Sheikh <italic>et al.</italic> 2008</xref>; <xref ref-type="bibr" rid="bibr28-2040620713489144">de la Chapelle <italic>et al.</italic> 1993</xref>; <xref ref-type="bibr" rid="bibr118-2040620713489144">Prchal, 2005</xref>; <xref ref-type="bibr" rid="bibr119-2040620713489144">Prchal <italic>et al.</italic> 1985</xref>]. Approximately 10–20% of all PFCP cases carry a truncating <italic>EPOR</italic> mutation, but the molecular basis for the remaining families remains unclear, despite extensive genetic investigations focusing on components the EPO pathway and regulation of <italic>EPO</italic> expression. Constitutional mutations in genes encoding components of the oxygen sensing pathways have been characterized in a small minority of familial polycythaemias with inappropriately normal or high circulating EPO levels. The best characterized are autosomal recessive mutations in the von Hippel–Lindau (<italic>VHL</italic>) gene, which impair the rate of ubiquitin-mediated degradation of the transcription factor hypoxia-induced factor (<italic>HIF</italic>)-1α. Consequently, raised <italic>HIF-1α</italic> heterodimers upregulate expression of <italic>EPO</italic> and other genes, stimulating erythrocytosis and causing other pathological consequences such as thrombocytosis and cerebrovascular events [<xref ref-type="bibr" rid="bibr10-2040620713489144">Ang <italic>et al.</italic> 2002</xref>]. <italic>VHL</italic> mutations were first characterized in patients with hereditary erythrocytosis from the Chuvash Republic in central Asia where the homozygous <italic>VHL</italic> (598C&gt;T) mutation is endemic [<xref ref-type="bibr" rid="bibr10-2040620713489144">Ang <italic>et al.</italic> 2002</xref>; <xref ref-type="bibr" rid="bibr132-2040620713489144">Sergeyeva <italic>et al.</italic> 1997</xref>] but there are different <italic>VHL</italic> mutations that have been detected in pedigrees from different ethnic groups [<xref ref-type="bibr" rid="bibr17-2040620713489144">Bento <italic>et al.</italic> 2005</xref>; <xref ref-type="bibr" rid="bibr22-2040620713489144">Cario <italic>et al.</italic> 2005</xref>; <xref ref-type="bibr" rid="bibr107-2040620713489144">Pastore <italic>et al.</italic> 2003</xref>]. Patients with homozygous <italic>VHL</italic> mutations do not develop tumours that are characteristic of the classical autosomal dominant <italic>VHL</italic> syndrome with a high incidence of malignant and benign neoplasms of the central nervous system and kidneys [<xref ref-type="bibr" rid="bibr68-2040620713489144">Kim and Kaelin, 2004</xref>]. In addition, constitutional missense mutations of the prolyl hydroxylase domain protein 2 (<italic>PHD2</italic>) have been reported, also causing erythrocytosis in a small number of families [<xref ref-type="bibr" rid="bibr5-2040620713489144">Albiero <italic>et al.</italic> 2012</xref>; <xref ref-type="bibr" rid="bibr68-2040620713489144">Kim and Kaelin, 2004</xref>; <xref ref-type="bibr" rid="bibr77-2040620713489144">Ladroue <italic>et al.</italic> 2012</xref>; <xref ref-type="bibr" rid="bibr112-2040620713489144">Percy <italic>et al.</italic> 2006</xref>, <xref ref-type="bibr" rid="bibr109-2040620713489144">2007a</xref>]. PHD2 is critical for mounting a correct response to hypoxia, as it mediates oxygen-dependent hydroxylation of HIF1α on proline residues, facilitating binding of VHL to HIF1α, and necessary proteasomal degradation. <italic>HIF2α</italic> may also be targeted by missense mutations in familial erythrocytosis [<xref ref-type="bibr" rid="bibr42-2040620713489144">Gale <italic>et al.</italic> 2008</xref>; <xref ref-type="bibr" rid="bibr88-2040620713489144">Martini <italic>et al.</italic> 2008</xref>; <xref ref-type="bibr" rid="bibr108-2040620713489144">Percy <italic>et al.</italic> 2008a</xref>, <xref ref-type="bibr" rid="bibr110-2040620713489144">2008b</xref>]. Functional studies indicate <italic>HIF2α</italic> mutations impair both PHD-2-induced hydroxylation of HIF2α, and the subsequent recognition of the hydroxylated HIF2α by VHL, leading to enhanced stabilisation of HIF2α and transcriptional upregulation of EPO [<xref ref-type="bibr" rid="bibr41-2040620713489144">Furlow <italic>et al.</italic> 2009</xref>].</p>
<p>Hereditary thrombocythaemia (also called familial thrombocytosis) has been linked to defects in the thromobopoietin signalling pathway, particularly mutations that target thromobopoietin (<italic>TPO)</italic> or its receptor (<italic>MPL</italic>). Affected individuals have elevated circulating levels of TPO, which aberrantly stimulates megakaryopoiesis and cause excessive platelet production, without any involvement of other lineages. It has long been known that for some hereditary thrombocytosis cases, elevated TPO levels are a consequence of increased translational efficiency of <italic>TPO</italic>, caused either by a G to C mutation [<xref ref-type="bibr" rid="bibr86-2040620713489144">Liu <italic>et al.</italic> 2008</xref>; <xref ref-type="bibr" rid="bibr149-2040620713489144">Wiestner <italic>et al.</italic> 1998</xref>] or a one-base-pair deletion [<xref ref-type="bibr" rid="bibr43-2040620713489144">Ghilardi and Skoda, 1999</xref>; <xref ref-type="bibr" rid="bibr44-2040620713489144">Ghilardi <italic>et al.</italic> 1999</xref>; <xref ref-type="bibr" rid="bibr70-2040620713489144">Kondo <italic>et al.</italic> 1998</xref>] affecting the splice donor site of intron 3. These mutations lead to <italic>TPO</italic> mRNAs with shortened 5’ untranslated regions that are more efficiently translated into mature protein than normal transcripts. Hereditary thrombocythaemia cases typically have an earlier onset of disease than those with sporadic ET, but share similar frequencies of thrombosis and haemorrhagic episodes.</p>
<p>There are also rare examples of activating <italic>MPL</italic> mutations passed through the germline, all associated with marked thrombocytosis and other myeloproliferative features, including splenomegaly, bone marrow fibrosis and higher risk of thrombosis. Some of these <italic>MPL</italic> mutations activate signalling pathways <italic>in vitro</italic>, and include amino acid changes S505N [<xref ref-type="bibr" rid="bibr30-2040620713489144">Ding <italic>et al.</italic> 2004</xref>; <xref ref-type="bibr" rid="bibr140-2040620713489144">Teofili <italic>et al.</italic> 2010</xref>], P106L [<xref ref-type="bibr" rid="bibr33-2040620713489144">El-Harith <italic>et al.</italic> 2009</xref>], and W515R [<xref ref-type="bibr" rid="bibr146-2040620713489144">Vilaine <italic>et al.</italic> 2012</xref>]. Interestingly, <italic>MPL</italic> K39N is a functional polymorphism restricted to the African American population, whereby the presence of one risk allele was reported to correlate with elevated platelets in the peripheral blood and presence of two copies was linked to severe thrombocytosis [<xref ref-type="bibr" rid="bibr92-2040620713489144">Moliterno <italic>et al.</italic> 2004</xref>]. Finally, there are isolated examples where inherited <italic>JAK2</italic> mutations segregate with features of disease; <italic>JAK2</italic> mutations V617I, R564Q, and H608N are associated with a phenotype characterized by thrombocytosis and high penetrance [<xref ref-type="bibr" rid="bibr36-2040620713489144">Etheridge <italic>et al.</italic> 2011</xref>; <xref ref-type="bibr" rid="bibr90-2040620713489144">Mead <italic>et al.</italic> 2012</xref>; <xref ref-type="bibr" rid="bibr121-2040620713489144">Rumi <italic>et al.</italic> 2012</xref>]. It appears that these mutations are more weakly activating that V617F, which may explain their ability to be passed through the germline.</p>
</sec>
<sec id="section11-2040620713489144" sec-type="conclusions">
<title>Conclusions</title>
<p>Knowledge about the genetic basis of sporadic MPN has increased enormously since the discovery of the <italic>JAK2</italic> V617F mutation, and this pace of progress is set to continue as new sequencing technologies further characterize new somatically acquired mutations. Furthermore, the characterization of <italic>JAK2</italic> 46/1 as a strong, common risk factor for the acquisition of V617F mutations was an important finding in terms of understanding genetic predisposition to MPN, hinted at by family and epidemiological studies. It is clear that germline factors play an important role in the pathogenesis of MPN, and it will be informative to see how this inherited variation modifies initiation, phenotype, clinical course and transformation driven by acquired mutations (<xref ref-type="fig" rid="fig2-2040620713489144">Figure 2</xref>). Further candidate and systematic studies will define more risk variants with variable frequencies and degrees of penetrance, but none are expected to be as striking as that observed for <italic>JAK2</italic> 46/1. Far less is known about what drives familial MPN, but it is expected next-generation sequencing will enable the discovery of further rare, highly penetrant variants. Finally, environmental and lifestyle influences on susceptibility to MPN have been investigated and reviewed elsewhere [<xref ref-type="bibr" rid="bibr8-2040620713489144">Anderson <italic>et al.</italic> 2011b</xref>]. These studies have mainly focused on exposures to various chemicals through lifestyle choices or occupation, and despite the vast heterogeneity in defining such hard to measure risks, there are recurrent reports linking exposure to benzene to the development of PV [<xref ref-type="bibr" rid="bibr3-2040620713489144">Aksoy, 1980</xref>; <xref ref-type="bibr" rid="bibr19-2040620713489144">Bernardini <italic>et al.</italic> 2005</xref>]. An ultimate goal would be to try to understand how rare and common germline factors, somatically acquired mutations and environmental modifiers all contribute to the development and clinical course of MPN.</p>
<fig id="fig2-2040620713489144" position="float">
<label>Figure 2.</label>
<caption>
<p>Inherited factors predispose to the development and influence the clinical course of MPN.</p>
</caption>
<graphic xlink:href="10.1177_2040620713489144-fig2.tif"/>
</fig>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</fn>
<fn fn-type="conflict">
<label>Conflict of interest statement</label>
<p>The authors declare that there are no conflicts of interest.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Abdel-Wahab</surname><given-names>O.</given-names></name>
<name><surname>Pardanani</surname><given-names>A.</given-names></name>
<name><surname>Rampal</surname><given-names>R.</given-names></name>
<name><surname>Lasho</surname><given-names>T.</given-names></name>
<name><surname>Levine</surname><given-names>R.</given-names></name>
<name><surname>Tefferi</surname><given-names>A.</given-names></name>
</person-group> (<year>2011</year>) <article-title>DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms</article-title>. <source>Leukemia</source> <volume>25</volume>: <fpage>1219</fpage>–<lpage>1220</lpage>.</citation>
</ref>
<ref id="bibr2-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Aguiar</surname><given-names>R.</given-names></name>
<name><surname>Chase</surname><given-names>A.</given-names></name>
<name><surname>Coulthard</surname><given-names>S.</given-names></name>
<name><surname>Macdonald</surname><given-names>D.</given-names></name>
<name><surname>Carapeti</surname><given-names>M.</given-names></name>
<name><surname>Reiter</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>1997</year>) <article-title>Abnormalities of chromosome band 8p11 in leukemia: two clinical syndromes can be distinguished on the basis of MOZ involvement</article-title>. <source>Blood</source> <volume>90</volume>: <fpage>3130</fpage>–<lpage>3135</lpage>.</citation>
</ref>
<ref id="bibr3-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Aksoy</surname><given-names>M.</given-names></name>
</person-group> (<year>1980</year>) <article-title>Malignancies due to occupational exposure to benzene</article-title>. <source>Haematologica</source> <volume>65</volume>.</citation>
</ref>
<ref id="bibr4-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Al-Sheikh</surname><given-names>M.</given-names></name>
<name><surname>Mazurier</surname><given-names>E.</given-names></name>
<name><surname>Gardie</surname><given-names>B.</given-names></name>
<name><surname>Casadevall</surname><given-names>N.</given-names></name>
<name><surname>Galacteros</surname><given-names>F.</given-names></name>
<name><surname>Goossens</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>A study of 36 unrelated cases with pure erythrocytosis revealed three new mutations in the erythropoietin receptor gene</article-title>. <source>Haematologica</source> <volume>93</volume>: <fpage>1072</fpage>–<lpage>1075</lpage>.</citation>
</ref>
<ref id="bibr5-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Albiero</surname><given-names>E.</given-names></name>
<name><surname>Ruggeri</surname><given-names>M.</given-names></name>
<name><surname>Fortuna</surname><given-names>S.</given-names></name>
<name><surname>Finotto</surname><given-names>S.</given-names></name>
<name><surname>Bernardi</surname><given-names>M.</given-names></name>
<name><surname>Madeo</surname><given-names>D.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Isolated erythrocytosis: study of 67 patients and identification of three novel germ-line mutations in the prolyl hydroxylase domain protein 2 (PHD2) gene</article-title>. <source>Haematologica</source> <volume>97</volume>: <fpage>123</fpage>–<lpage>127</lpage>.</citation>
</ref>
<ref id="bibr6-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alvarez-Larran</surname><given-names>A.</given-names></name>
<name><surname>Angona</surname><given-names>A.</given-names></name>
<name><surname>Martinez-Aviles</surname><given-names>L.</given-names></name>
<name><surname>Bellosillo</surname><given-names>B.</given-names></name>
<name><surname>Besses</surname><given-names>C.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Influence of JAK2 46/1 haplotype in the natural evolution of JAK2V617F allele burden in patients with myeloproliferative neoplasms</article-title>. <source>Leuk Res</source> <volume>36</volume>: <fpage>324</fpage>–<lpage>326</lpage>.</citation>
</ref>
<ref id="bibr7-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Anderson</surname><given-names>C.</given-names></name>
<name><surname>Boucher</surname><given-names>G.</given-names></name>
<name><surname>Lees</surname><given-names>C.</given-names></name>
<name><surname>Franke</surname><given-names>A.</given-names></name>
<name><surname>D’Amato</surname><given-names>M.</given-names></name>
<name><surname>Taylor</surname><given-names>K.</given-names></name><etal/>
</person-group>. (<year>2011a</year>) <article-title>Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47</article-title>. <source>Nat Genet</source> <volume>43</volume>: <fpage>246</fpage>–<lpage>252</lpage>.</citation>
</ref>
<ref id="bibr8-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Anderson</surname><given-names>L.</given-names></name>
<name><surname>Duncombe</surname><given-names>A.</given-names></name>
<name><surname>Hughes</surname><given-names>M.</given-names></name>
<name><surname>Mills</surname><given-names>M.</given-names></name>
<name><surname>Wilson</surname><given-names>J.</given-names></name>
<name><surname>McMullin</surname><given-names>M.</given-names></name>
</person-group> (<year>2011b</year>) <article-title>Environmental, lifestyle, and familial/ethnic factors associated with myeloproliferative neoplasms</article-title>. <source>Am J Hematol</source> <volume>87</volume>: <fpage>175</fpage>–<lpage>182</lpage>.</citation>
</ref>
<ref id="bibr9-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Andrikovics</surname><given-names>H.</given-names></name>
<name><surname>Nahajevszky</surname><given-names>S.</given-names></name>
<name><surname>Koszarska</surname><given-names>M.</given-names></name>
<name><surname>Meggyesi</surname><given-names>N.</given-names></name>
<name><surname>Bors</surname><given-names>A.</given-names></name>
<name><surname>Halm</surname><given-names>G.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>JAK2 46/1 haplotype analysis in myeloproliferative neoplasms and acute myeloid leukemia</article-title>. <source>Leukemia</source> <volume>24</volume>: <fpage>1809</fpage>–<lpage>1813</lpage>.</citation>
</ref>
<ref id="bibr10-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ang</surname><given-names>S.</given-names></name>
<name><surname>Chen</surname><given-names>H.</given-names></name>
<name><surname>Hirota</surname><given-names>K.</given-names></name>
<name><surname>Gordeuk</surname><given-names>V.</given-names></name>
<name><surname>Jelinek</surname><given-names>J.</given-names></name>
<name><surname>Guan</surname><given-names>Y.</given-names></name><etal/>
</person-group>. (<year>2002</year>) <article-title>Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia</article-title>. <source>Nat Genet</source> <volume>32</volume>: <fpage>614</fpage>–<lpage>621</lpage>.</citation>
</ref>
<ref id="bibr11-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Assumpcao</surname><given-names>J.</given-names></name>
<name><surname>Seidinger</surname><given-names>A.</given-names></name>
<name><surname>Mastellaro</surname><given-names>M.</given-names></name>
<name><surname>Ribeiro</surname><given-names>R.</given-names></name>
<name><surname>Zambetti</surname><given-names>G.</given-names></name>
<name><surname>Ganti</surname><given-names>R.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Association of the germline TP53 R337H mutation with breast cancer in southern Brazil</article-title>. <source>BMC Cancer</source> <volume>8</volume>: <fpage>357</fpage>.</citation>
</ref>
<ref id="bibr12-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bacher</surname><given-names>U.</given-names></name>
<name><surname>Haferlach</surname><given-names>T.</given-names></name>
<name><surname>Kern</surname><given-names>W.</given-names></name>
<name><surname>Haferlach</surname><given-names>C.</given-names></name>
<name><surname>Schnittger</surname><given-names>S.</given-names></name>
</person-group> (<year>2007</year>) <article-title>A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia</article-title>. <source>Haematologica</source> <volume>92</volume>: <fpage>744</fpage>–<lpage>752</lpage>.</citation>
</ref>
<ref id="bibr13-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barosi</surname><given-names>G.</given-names></name>
<name><surname>Magrini</surname><given-names>U.</given-names></name>
<name><surname>Gale</surname><given-names>R.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Does auto-immunity contribute to anemia in myeloproliferative neoplasms (MPN)-associated myelofibrosis?</article-title> <source>Leuk Res</source> <volume>34</volume>: <fpage>1119</fpage>–<lpage>1120</lpage>.</citation>
</ref>
<ref id="bibr14-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barrett</surname><given-names>J.</given-names></name>
<name><surname>Hansoul</surname><given-names>S.</given-names></name>
<name><surname>Nicolae</surname><given-names>D.</given-names></name>
<name><surname>Cho</surname><given-names>J.</given-names></name>
<name><surname>Duerr</surname><given-names>R.</given-names></name>
<name><surname>Rioux</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease</article-title>. <source>Nat Genet</source> <volume>40</volume>: <fpage>955</fpage>–<lpage>962</lpage>.</citation>
</ref>
<ref id="bibr15-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Baxter</surname><given-names>E.</given-names></name>
<name><surname>Scott</surname><given-names>L.</given-names></name>
<name><surname>Campbell</surname><given-names>P.</given-names></name>
<name><surname>East</surname><given-names>C.</given-names></name>
<name><surname>Fourouclas</surname><given-names>N.</given-names></name>
<name><surname>Swanton</surname><given-names>S.</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders</article-title>. <source>Lancet</source> <volume>365</volume>: <fpage>1054</fpage>–<lpage>1061</lpage>.</citation>
</ref>
<ref id="bibr16-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bellanne-Chantelot</surname><given-names>C.</given-names></name>
<name><surname>Chaumarel</surname><given-names>I.</given-names></name>
<name><surname>Labopin</surname><given-names>M.</given-names></name>
<name><surname>Bellanger</surname><given-names>F.</given-names></name>
<name><surname>Barbu</surname><given-names>V.</given-names></name>
<name><surname>De Toma</surname><given-names>C.</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders</article-title>. <source>Blood</source> <volume>108</volume>: <fpage>346</fpage>–<lpage>352</lpage>.</citation>
</ref>
<ref id="bibr17-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bento</surname><given-names>M.</given-names></name>
<name><surname>Chang</surname><given-names>K.</given-names></name>
<name><surname>Guan</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>E.</given-names></name>
<name><surname>Caldas</surname><given-names>G.</given-names></name>
<name><surname>Gatti</surname><given-names>R.</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>Congenital polycythemia with homozygous and heterozygous mutations of von Hippel–Lindau gene: five new Caucasian patients</article-title>. <source>Haematologica</source> <volume>90</volume>: <fpage>128</fpage>–<lpage>129</lpage>.</citation>
</ref>
<ref id="bibr18-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bercovich</surname><given-names>D.</given-names></name>
<name><surname>Ganmore</surname><given-names>I.</given-names></name>
<name><surname>Scott</surname><given-names>L.</given-names></name>
<name><surname>Wainreb</surname><given-names>G.</given-names></name>
<name><surname>Birger</surname><given-names>Y.</given-names></name>
<name><surname>Elimelech</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down’s syndrome</article-title>. <source>Lancet</source> <volume>372</volume>: <fpage>1484</fpage>–<lpage>1492</lpage>.</citation>
</ref>
<ref id="bibr19-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bernardini</surname><given-names>P.</given-names></name>
<name><surname>Giannandrea</surname><given-names>F.</given-names></name>
<name><surname>Voso</surname><given-names>M.</given-names></name>
<name><surname>Sica</surname><given-names>S.</given-names></name>
</person-group> (<year>2005</year>) <article-title>[Myeloproliferative disorders due to the use of gasoline as a solvent: report of three cases]</article-title>. <source>Med Lav</source> <volume>96</volume>: <fpage>119</fpage>–<lpage>125</lpage>.</citation>
</ref>
<ref id="bibr20-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Campbell</surname><given-names>P.</given-names></name>
<name><surname>Green</surname><given-names>A.</given-names></name>
</person-group> (<year>2006</year>) <article-title>The myeloproliferative disorders</article-title>. <source>N Engl J Med</source> <volume>355</volume>: <fpage>2452</fpage>–<lpage>2466</lpage>.</citation>
</ref>
<ref id="bibr21-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carbuccia</surname><given-names>N.</given-names></name>
<name><surname>Murati</surname><given-names>A.</given-names></name>
<name><surname>Trouplin</surname><given-names>V.</given-names></name>
<name><surname>Brecqueville</surname><given-names>M.</given-names></name>
<name><surname>Adelaide</surname><given-names>J.</given-names></name>
<name><surname>Rey</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Mutations of ASXL1 gene in myeloproliferative neoplasms</article-title>. <source>Leukemia</source> <volume>23</volume>: <fpage>2183</fpage>–<lpage>2186</lpage>.</citation>
</ref>
<ref id="bibr22-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cario</surname><given-names>H.</given-names></name>
<name><surname>Schwarz</surname><given-names>K.</given-names></name>
<name><surname>Jorch</surname><given-names>N.</given-names></name>
<name><surname>Kyank</surname><given-names>U.</given-names></name>
<name><surname>Petrides</surname><given-names>P.</given-names></name>
<name><surname>Schneider</surname><given-names>D.</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>Mutations in the von Hippel-Lindau (VHL) tumor suppressor gene and VHL-haplotype analysis in patients with presumable congenital erythrocytosis</article-title>. <source>Haematologica</source> <volume>90</volume>: <fpage>19</fpage>–<lpage>24</lpage>.</citation>
</ref>
<ref id="bibr23-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chaiter</surname><given-names>Y.</given-names></name>
<name><surname>Brenner</surname><given-names>B.</given-names></name>
<name><surname>Aghai</surname><given-names>E.</given-names></name>
<name><surname>Tatarsky</surname><given-names>I.</given-names></name>
</person-group> (<year>1992</year>) <article-title>High incidence of myeloproliferative disorders in Ashkenazi Jews in northern Israel</article-title>. <source>Leuk Lymphoma</source> <volume>7</volume>: <fpage>251</fpage>–<lpage>255</lpage>.</citation>
</ref>
<ref id="bibr24-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>E.</given-names></name>
<name><surname>Beer</surname><given-names>P.</given-names></name>
<name><surname>Godfrey</surname><given-names>A.</given-names></name>
<name><surname>Ortmann</surname><given-names>C.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Costa-Pereira</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling</article-title>. <source>Cancer Cell</source> <volume>18</volume>: <fpage>524</fpage>–<lpage>535</lpage>.</citation>
</ref>
<ref id="bibr25-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cools</surname><given-names>J.</given-names></name>
<name><surname>DeAngelo</surname><given-names>D.</given-names></name>
<name><surname>Gotlib</surname><given-names>J.</given-names></name>
<name><surname>Stover</surname><given-names>E.</given-names></name>
<name><surname>Legare</surname><given-names>R.</given-names></name>
<name><surname>Cortes</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2003</year>) <article-title>A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome</article-title>. <source>N Engl J Med</source> <volume>348</volume>: <fpage>1201</fpage>–<lpage>1214</lpage>.</citation>
</ref>
<ref id="bibr26-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cross</surname><given-names>N.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Genetic and epigenetic complexity in myeloproliferative neoplasms</article-title>. <source>Hematology Am Soc Hematol Educ Program</source> <volume>2011</volume>: <fpage>208</fpage>–<lpage>214</lpage>.</citation>
</ref>
<ref id="bibr27-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cross</surname><given-names>N.</given-names></name>
<name><surname>Reiter</surname><given-names>A.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders</article-title>. <source>Acta Haematologica</source> <volume>119</volume>: <fpage>199</fpage>–<lpage>206</lpage>.</citation>
</ref>
<ref id="bibr28-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>de la Chapelle</surname><given-names>A.</given-names></name>
<name><surname>Traskelin</surname><given-names>A.</given-names></name>
<name><surname>Juvonen</surname><given-names>E.</given-names></name>
</person-group> (<year>1993</year>) <article-title>Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>90</volume>: <fpage>4495</fpage>–<lpage>4499</lpage>.</citation>
</ref>
<ref id="bibr29-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Delhommeau</surname><given-names>F.</given-names></name>
<name><surname>Dupont</surname><given-names>S.</given-names></name>
<name><surname>Della Valle</surname><given-names>V.</given-names></name>
<name><surname>James</surname><given-names>C.</given-names></name>
<name><surname>Trannoy</surname><given-names>S.</given-names></name>
<name><surname>Masse</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Mutation in TET2 in myeloid cancers</article-title>. <source>N Engl J Med</source> <volume>360</volume>: <fpage>2289</fpage>–<lpage>2301</lpage>.</citation>
</ref>
<ref id="bibr30-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ding</surname><given-names>J.</given-names></name>
<name><surname>Komatsu</surname><given-names>H.</given-names></name>
<name><surname>Wakita</surname><given-names>A.</given-names></name>
<name><surname>Kato-Uranishi</surname><given-names>M.</given-names></name>
<name><surname>Ito</surname><given-names>M.</given-names></name>
<name><surname>Satoh</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2004</year>) <article-title>Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin</article-title>. <source>Blood</source> <volume>103</volume>: <fpage>4198</fpage>–<lpage>4200</lpage>.</citation>
</ref>
<ref id="bibr31-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ding</surname><given-names>Y.</given-names></name>
<name><surname>Harada</surname><given-names>Y.</given-names></name>
<name><surname>Imagawa</surname><given-names>J.</given-names></name>
<name><surname>Kimura</surname><given-names>A.</given-names></name>
<name><surname>Harada</surname><given-names>H.</given-names></name>
</person-group> (<year>2009</year>) <article-title>AML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms</article-title>. <source>Blood</source> <volume>114</volume>: <fpage>5201</fpage>–<lpage>5205</lpage>.</citation>
</ref>
<ref id="bibr32-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dusa</surname><given-names>A.</given-names></name>
<name><surname>Staerk</surname><given-names>J.</given-names></name>
<name><surname>Elliott</surname><given-names>J.</given-names></name>
<name><surname>Pecquet</surname><given-names>C.</given-names></name>
<name><surname>Poirel</surname><given-names>H.</given-names></name>
<name><surname>Johnston</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Substitution of pseudokinase domain residue Val-617 by large non-polar amino acids causes activation of JAK2</article-title>. <source>J Biol Chem</source> <volume>283</volume>: <fpage>12941</fpage>–<lpage>12948</lpage>.</citation>
</ref>
<ref id="bibr33-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>El-Harith</surname><given-names>E.</given-names></name>
<name><surname>Roesl</surname><given-names>C.</given-names></name>
<name><surname>Ballmaier</surname><given-names>M.</given-names></name>
<name><surname>Germeshausen</surname><given-names>M.</given-names></name>
<name><surname>Frye-Boukhriss</surname><given-names>H.</given-names></name>
<name><surname>Von Neuhoff</surname><given-names>N.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Familial thrombocytosis caused by the novel germ-line mutation p.Pro106Leu in the MPL gene</article-title>. <source>Br J Haematol</source> <volume>144</volume>: <fpage>185</fpage>–<lpage>194</lpage>.</citation>
</ref>
<ref id="bibr34-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ellinghaus</surname><given-names>D.</given-names></name>
<name><surname>Ellinghaus</surname><given-names>E.</given-names></name>
<name><surname>Nair</surname><given-names>R.</given-names></name>
<name><surname>Stuart</surname><given-names>P.</given-names></name>
<name><surname>Esko</surname><given-names>T.</given-names></name>
<name><surname>Metspalu</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci</article-title>. <source>Am J Hum Genet</source> <volume>90</volume>: <fpage>636</fpage>–<lpage>647</lpage>.</citation>
</ref>
<ref id="bibr35-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ernst</surname><given-names>T.</given-names></name>
<name><surname>Chase</surname><given-names>A.</given-names></name>
<name><surname>Score</surname><given-names>J.</given-names></name>
<name><surname>Hidalgo-Curtis</surname><given-names>C.</given-names></name>
<name><surname>Bryant</surname><given-names>C.</given-names></name>
<name><surname>Jones</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders</article-title>. <source>Nat Genet</source> <volume>42</volume>: <fpage>722</fpage>–<lpage>726</lpage>.</citation>
</ref>
<ref id="bibr36-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Etheridge</surname><given-names>L.</given-names></name>
<name><surname>Corbo</surname><given-names>L.</given-names></name>
<name><surname>Kaushansky</surname><given-names>K.</given-names></name>
<name><surname>Chan</surname><given-names>E.</given-names></name>
<name><surname>Hitchcock</surname><given-names>I.</given-names></name>
</person-group> (<year>2011</year>) <article-title>A novel activating JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis (fET) via mechanisms distinct from JAK2V617F</article-title>. <source>ASH Annual Meeting Abstracts</source> <volume>118</volume>(<issue>21</issue>): <fpage>123</fpage>.</citation>
</ref>
<ref id="bibr37-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Falini</surname><given-names>B.</given-names></name>
<name><surname>Mecucci</surname><given-names>C.</given-names></name>
<name><surname>Tiacci</surname><given-names>E.</given-names></name>
<name><surname>Alcalay</surname><given-names>M.</given-names></name>
<name><surname>Rosati</surname><given-names>R.</given-names></name>
<name><surname>Pasqualucci</surname><given-names>L.</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype</article-title>. <source>N Engl J Med</source> <volume>352</volume>: <fpage>254</fpage>–<lpage>266</lpage>.</citation>
</ref>
<ref id="bibr38-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Figueroa</surname><given-names>M.</given-names></name>
<name><surname>Abdel-Wahab</surname><given-names>O.</given-names></name>
<name><surname>Lu</surname><given-names>C.</given-names></name>
<name><surname>Ward</surname><given-names>P.</given-names></name>
<name><surname>Patel</surname><given-names>J.</given-names></name>
<name><surname>Shih</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation</article-title>. <source>Cancer Cell</source> <volume>18</volume>: <fpage>553</fpage>–<lpage>567</lpage>.</citation>
</ref>
<ref id="bibr39-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Frederiksen</surname><given-names>H.</given-names></name>
<name><surname>Farkas</surname><given-names>D.</given-names></name>
<name><surname>Christiansen</surname><given-names>C.</given-names></name>
<name><surname>Hasselbalch</surname><given-names>H.</given-names></name>
<name><surname>Sorensen</surname><given-names>H.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study</article-title>. <source>Blood</source> <volume>118</volume>: <fpage>6515</fpage>–<lpage>6520</lpage>.</citation>
</ref>
<ref id="bibr40-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Furitsu</surname><given-names>T.</given-names></name>
<name><surname>Tsujimura</surname><given-names>T.</given-names></name>
<name><surname>Tono</surname><given-names>T.</given-names></name>
<name><surname>Ikeda</surname><given-names>H.</given-names></name>
<name><surname>Kitayama</surname><given-names>H.</given-names></name>
<name><surname>Koshimizu</surname><given-names>U.</given-names></name><etal/>
</person-group>. (<year>1993</year>) <article-title>Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product</article-title>. <source>J Clin Invest</source> <volume>92</volume>: <fpage>1736</fpage>–<lpage>1744</lpage>.</citation>
</ref>
<ref id="bibr41-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Furlow</surname><given-names>P.</given-names></name>
<name><surname>Percy</surname><given-names>M.</given-names></name>
<name><surname>Sutherland</surname><given-names>S.</given-names></name>
<name><surname>Bierl</surname><given-names>C.</given-names></name>
<name><surname>McMullin</surname><given-names>M.</given-names></name>
<name><surname>Master</surname><given-names>S.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Erythrocytosis-associated HIF-2alpha mutations demonstrate a critical role for residues C-terminal to the hydroxylacceptor proline</article-title>. <source>J Biol Chem</source> <volume>284</volume>: <fpage>9050</fpage>–<lpage>9058</lpage>.</citation>
</ref>
<ref id="bibr42-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gale</surname><given-names>D.</given-names></name>
<name><surname>Harten</surname><given-names>S.</given-names></name>
<name><surname>Reid</surname><given-names>C.</given-names></name>
<name><surname>Tuddenham</surname><given-names>E.</given-names></name>
<name><surname>Maxwell</surname><given-names>P.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Autosomal dominant erythrocytosis and pulmonary arterial hypertension associated with an activating HIF2 alpha mutation</article-title>. <source>Blood</source> <volume>112</volume>: <fpage>919</fpage>–<lpage>921</lpage>.</citation>
</ref>
<ref id="bibr43-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ghilardi</surname><given-names>N.</given-names></name>
<name><surname>Skoda</surname><given-names>R.</given-names></name>
</person-group> (<year>1999</year>) <article-title>A single-base deletion in the thrombopoietin (TPO) gene causes familial essential thrombocythemia through a mechanism of more efficient translation of TPO mRNA</article-title>. <source>Blood</source> <volume>94</volume>: <fpage>1480</fpage>–<lpage>1482</lpage>.</citation>
</ref>
<ref id="bibr44-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ghilardi</surname><given-names>N.</given-names></name>
<name><surname>Wiestner</surname><given-names>A.</given-names></name>
<name><surname>Kikuchi</surname><given-names>M.</given-names></name>
<name><surname>Ohsaka</surname><given-names>A.</given-names></name>
<name><surname>Skoda</surname><given-names>R.</given-names></name>
</person-group> (<year>1999</year>) <article-title>Hereditary thrombocythaemia in a Japanese family is caused by a novel point mutation in the thrombopoietin gene</article-title>. <source>Br J Haematol</source> <volume>107</volume>: <fpage>310</fpage>–<lpage>316</lpage>.</citation>
</ref>
<ref id="bibr45-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gieger</surname><given-names>C.</given-names></name>
<name><surname>Radhakrishnan</surname><given-names>A.</given-names></name>
<name><surname>Cvejic</surname><given-names>A.</given-names></name>
<name><surname>Tang</surname><given-names>W.</given-names></name>
<name><surname>Porcu</surname><given-names>E.</given-names></name>
<name><surname>Pistis</surname><given-names>G.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>New gene functions in megakaryopoiesis and platelet formation</article-title>. <source>Nature</source> <volume>480</volume>: <fpage>201</fpage>–<lpage>208</lpage>.</citation>
</ref>
<ref id="bibr46-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Godfrey</surname><given-names>A.</given-names></name>
<name><surname>Chen</surname><given-names>E.</given-names></name>
<name><surname>Pagano</surname><given-names>F.</given-names></name>
<name><surname>Ortmann</surname><given-names>C.</given-names></name>
<name><surname>Silber</surname><given-names>Y.</given-names></name>
<name><surname>Bellosillo</surname><given-names>B.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone</article-title>. <source>Blood</source> <volume>120</volume>: <fpage>2704</fpage>–<lpage>2707</lpage>.</citation>
</ref>
<ref id="bibr47-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Goldin</surname><given-names>L.</given-names></name>
<name><surname>Kristinsson</surname><given-names>S.</given-names></name>
<name><surname>Liang</surname><given-names>X.</given-names></name>
<name><surname>Derolf</surname><given-names>A.</given-names></name>
<name><surname>Landgren</surname><given-names>O.</given-names></name>
<name><surname>Bjorkholm</surname><given-names>M.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Familial aggregation of acute myeloid leukemia and myelodysplastic syndromes</article-title>. <source>J Clin Oncol</source> <volume>30</volume>: <fpage>179</fpage>–<lpage>183</lpage>.</citation>
</ref>
<ref id="bibr48-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gordeuk</surname><given-names>V.</given-names></name>
<name><surname>Stockton</surname><given-names>D.</given-names></name>
<name><surname>Prchal</surname><given-names>J.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Congenital polycythemias/erythrocytoses</article-title>. <source>Haematologica</source> <volume>90</volume>: <fpage>109</fpage>–<lpage>116</lpage>.</citation>
</ref>
<ref id="bibr49-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grand</surname><given-names>F.</given-names></name>
<name><surname>Hidalgo-Curtis</surname><given-names>C.</given-names></name>
<name><surname>Ernst</surname><given-names>T.</given-names></name>
<name><surname>Zoi</surname><given-names>K.</given-names></name>
<name><surname>Zoi</surname><given-names>C.</given-names></name>
<name><surname>McGuire</surname><given-names>C.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms</article-title>. <source>Blood</source> <volume>113</volume>: <fpage>6182</fpage>–<lpage>6192</lpage>.</citation>
</ref>
<ref id="bibr50-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Green</surname><given-names>A.</given-names></name>
<name><surname>Beer</surname><given-names>P.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms</article-title>. <source>N Engl J Med</source> <volume>362</volume>: <fpage>369</fpage>–<lpage>370</lpage>.</citation>
</ref>
<ref id="bibr51-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Guglielmelli</surname><given-names>P.</given-names></name>
<name><surname>Biamonte</surname><given-names>F.</given-names></name>
<name><surname>Spolverini</surname><given-names>A.</given-names></name>
<name><surname>Pieri</surname><given-names>L.</given-names></name>
<name><surname>Isgro</surname><given-names>A.</given-names></name>
<name><surname>Antonioli</surname><given-names>E.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis</article-title>. <source>Leukemia</source> <volume>24</volume>: <fpage>1533</fpage>–<lpage>1537</lpage>.</citation>
</ref>
<ref id="bibr52-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Harutyunyan</surname><given-names>A.</given-names></name>
<name><surname>Gisslinger</surname><given-names>B.</given-names></name>
<name><surname>Klampfl</surname><given-names>T.</given-names></name>
<name><surname>Berg</surname><given-names>T.</given-names></name>
<name><surname>Bagienski</surname><given-names>K.</given-names></name>
<name><surname>Gisslinger</surname><given-names>H.</given-names></name><etal/>
</person-group>. (<year>2011a</year>) <article-title>Rare germline variants in regions of loss of heterozygosity may influence clinical course of hematological malignancies</article-title>. <source>Leukemia</source> <volume>25</volume>: <fpage>1782</fpage>–<lpage>1784</lpage>.</citation>
</ref>
<ref id="bibr53-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Harutyunyan</surname><given-names>A.</given-names></name>
<name><surname>Klampfl</surname><given-names>T.</given-names></name>
<name><surname>Cazzola</surname><given-names>M.</given-names></name>
<name><surname>Kralovics</surname><given-names>R.</given-names></name>
</person-group> (<year>2011b</year>) <article-title>p53 lesions in leukemic transformation</article-title>. <source>N Engl J Med</source> <volume>364</volume>: <fpage>488</fpage>–<lpage>490</lpage>.</citation>
</ref>
<ref id="bibr54-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hernandez-Boluda</surname><given-names>J.</given-names></name>
<name><surname>Pereira</surname><given-names>A.</given-names></name>
<name><surname>Cervantes</surname><given-names>F.</given-names></name>
<name><surname>Alvarez-Larran</surname><given-names>A.</given-names></name>
<name><surname>Collado</surname><given-names>M.</given-names></name>
<name><surname>Such</surname><given-names>E.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>A polymorphism in the XPD gene predisposes to leukemic transformation and new nonmyeloid malignancies in essential thrombocythemia and polycythemia vera</article-title>. <source>Blood</source> <volume>119</volume>: <fpage>5221</fpage>–<lpage>5228</lpage>.</citation>
</ref>
<ref id="bibr55-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hertzberg</surname><given-names>L.</given-names></name>
<name><surname>Vendramini</surname><given-names>E.</given-names></name>
<name><surname>Ganmore</surname><given-names>I.</given-names></name>
<name><surname>Cazzaniga</surname><given-names>G.</given-names></name>
<name><surname>Schmitz</surname><given-names>M.</given-names></name>
<name><surname>Chalker</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group</article-title>. <source>Blood</source> <volume>115</volume>: <fpage>1006</fpage>–<lpage>1017</lpage>.</citation>
</ref>
<ref id="bibr56-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hinds</surname><given-names>D.</given-names></name>
<name><surname>Barnholt</surname><given-names>K.</given-names></name>
<name><surname>Zehnder</surname><given-names>J.</given-names></name>
<name><surname>Kiefer</surname><given-names>A.</given-names></name>
<name><surname>Do</surname><given-names>C.</given-names></name>
<name><surname>Eriksson</surname><given-names>N.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>A germline variant in the TERT gene is a novel predisposition allele associated with myeloproliferative neoplasms</article-title>. <source>ASH Annual Meeting Abstracts</source> <volume>120</volume>(<issue>21</issue>): <fpage>707</fpage>.</citation>
</ref>
<ref id="bibr57-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hoffman</surname><given-names>R.</given-names></name>
<name><surname>Rondelli</surname><given-names>D.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Biology and treatment of primary myelofibrosis</article-title>. <source>Hematology Am Soc Hematol Educ Program</source> <volume>2007</volume>: <fpage>346</fpage>–<lpage>354</lpage>.</citation>
</ref>
<ref id="bibr58-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hultcrantz</surname><given-names>M.</given-names></name>
<name><surname>Kristinsson</surname><given-names>S.</given-names></name>
<name><surname>Andersson</surname><given-names>T.</given-names></name>
<name><surname>Landgren</surname><given-names>O.</given-names></name>
<name><surname>Eloranta</surname><given-names>S.</given-names></name>
<name><surname>Derolf</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study</article-title>. <source>J Clin Oncol</source> <volume>30</volume>: <fpage>2995</fpage>–<lpage>3001</lpage>.</citation>
</ref>
<ref id="bibr59-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hussein</surname><given-names>K.</given-names></name>
<name><surname>Bock</surname><given-names>O.</given-names></name>
<name><surname>Seegers</surname><given-names>A.</given-names></name>
<name><surname>Flasshove</surname><given-names>M.</given-names></name>
<name><surname>Henneke</surname><given-names>F.</given-names></name>
<name><surname>Buesche</surname><given-names>G.</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation</article-title>. <source>Blood</source> <volume>109</volume>: <fpage>4106</fpage>–<lpage>4107</lpage>.</citation>
</ref>
<ref id="bibr60-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jager</surname><given-names>R.</given-names></name>
<name><surname>Gisslinger</surname><given-names>H.</given-names></name>
<name><surname>Passamonti</surname><given-names>F.</given-names></name>
<name><surname>Rumi</surname><given-names>E.</given-names></name>
<name><surname>Berg</surname><given-names>T.</given-names></name>
<name><surname>Gisslinger</surname><given-names>B.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Deletions of the transcription factor Ikaros in myeloproliferative neoplasms</article-title>. <source>Leukemia</source> <volume>24</volume>: <fpage>1290</fpage>–<lpage>1298</lpage>.</citation>
</ref>
<ref id="bibr61-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>James</surname><given-names>C.</given-names></name>
<name><surname>Ugo</surname><given-names>V.</given-names></name>
<name><surname>Le Couedic</surname><given-names>J.</given-names></name>
<name><surname>Staerk</surname><given-names>J.</given-names></name>
<name><surname>Delhommeau</surname><given-names>F.</given-names></name>
<name><surname>Lacout</surname><given-names>C.</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera</article-title>. <source>Nature</source> <volume>434</volume>: <fpage>1144</fpage>–<lpage>1148</lpage>.</citation>
</ref>
<ref id="bibr62-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Johansson</surname><given-names>P.</given-names></name>
<name><surname>Kutti</surname><given-names>J.</given-names></name>
<name><surname>Andreasson</surname><given-names>B.</given-names></name>
<name><surname>Safai-Kutti</surname><given-names>S.</given-names></name>
<name><surname>Vilen</surname><given-names>L.</given-names></name>
<name><surname>Wedel</surname><given-names>H.</given-names></name><etal/>
</person-group>. (<year>2004</year>) <article-title>Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Goteborg, Sweden, during 1983–99</article-title>. <source>J Intern Med</source> <volume>256</volume>: <fpage>161</fpage>–<lpage>165</lpage>.</citation>
</ref>
<ref id="bibr63-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jones</surname><given-names>A.</given-names></name>
<name><surname>Campbell</surname><given-names>P.</given-names></name>
<name><surname>Beer</surname><given-names>P.</given-names></name>
<name><surname>Schnittger</surname><given-names>S.</given-names></name>
<name><surname>Vannucchi</surname><given-names>A.</given-names></name>
<name><surname>Zoi</surname><given-names>K.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms</article-title>. <source>Blood</source> <volume>115</volume>: <fpage>4517</fpage>–<lpage>4523</lpage>.</citation>
</ref>
<ref id="bibr64-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jones</surname><given-names>A.</given-names></name>
<name><surname>Chase</surname><given-names>A.</given-names></name>
<name><surname>Silver</surname><given-names>R.</given-names></name>
<name><surname>Oscier</surname><given-names>D.</given-names></name>
<name><surname>Zoi</surname><given-names>K.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms</article-title>. <source>Nat Genet</source> <volume>41</volume>: <fpage>446</fpage>–<lpage>449</lpage>.</citation>
</ref>
<ref id="bibr65-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jones</surname><given-names>A.</given-names></name>
<name><surname>Cross</surname><given-names>N.</given-names></name>
</person-group> (<year>2010</year>) <article-title>No association between myeloproliferative neoplasms and the Crohn’s disease-associated STAT3 predisposition SNP rs744166</article-title>. <source>Haematologica</source> <volume>95</volume>: <fpage>1226</fpage>–<lpage>1227</lpage>.</citation>
</ref>
<ref id="bibr66-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kearney</surname><given-names>L.</given-names></name>
<name><surname>Gonzalez De Castro</surname><given-names>D.</given-names></name>
<name><surname>Yeung</surname><given-names>J.</given-names></name>
<name><surname>Procter</surname><given-names>J.</given-names></name>
<name><surname>Horsley</surname><given-names>S.</given-names></name>
<name><surname>Eguchi-Ishimae</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia</article-title>. <source>Blood</source> <volume>113</volume>: <fpage>646</fpage>–<lpage>648</lpage>.</citation>
</ref>
<ref id="bibr67-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kilpivaara</surname><given-names>O.</given-names></name>
<name><surname>Mukherjee</surname><given-names>S.</given-names></name>
<name><surname>Schram</surname><given-names>A.</given-names></name>
<name><surname>Wadleigh</surname><given-names>M.</given-names></name>
<name><surname>Mullally</surname><given-names>A.</given-names></name>
<name><surname>Ebert</surname><given-names>B.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms</article-title>. <source>Nat Genet</source> <volume>41</volume>: <fpage>455</fpage>–<lpage>459</lpage>.</citation>
</ref>
<ref id="bibr68-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kim</surname><given-names>W.</given-names></name>
<name><surname>Kaelin</surname><given-names>W.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Role of VHL gene mutation in human cancer</article-title>. <source>J Clin Oncol</source> <volume>22</volume>: <fpage>4991</fpage>–<lpage>5004</lpage>.</citation>
</ref>
<ref id="bibr69-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Klampfl</surname><given-names>T.</given-names></name>
<name><surname>Harutyunyan</surname><given-names>A.</given-names></name>
<name><surname>Berg</surname><given-names>T.</given-names></name>
<name><surname>Gisslinger</surname><given-names>B.</given-names></name>
<name><surname>Schalling</surname><given-names>M.</given-names></name>
<name><surname>Bagienski</surname><given-names>K.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression</article-title>. <source>Blood</source> <volume>118</volume>: <fpage>167</fpage>–<lpage>176</lpage>.</citation>
</ref>
<ref id="bibr70-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kondo</surname><given-names>T.</given-names></name>
<name><surname>Okabe</surname><given-names>M.</given-names></name>
<name><surname>Sanada</surname><given-names>M.</given-names></name>
<name><surname>Kurosawa</surname><given-names>M.</given-names></name>
<name><surname>Suzuki</surname><given-names>S.</given-names></name>
<name><surname>Kobayashi</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>1998</year>) <article-title>Familial essential thrombocythemia associated with one-base deletion in the 5’-untranslated region of the thrombopoietin gene</article-title>. <source>Blood</source> <volume>92</volume>: <fpage>1091</fpage>–<lpage>1096</lpage>.</citation>
</ref>
<ref id="bibr71-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kouroupi</surname><given-names>E.</given-names></name>
<name><surname>Kiladjian</surname><given-names>J.</given-names></name>
<name><surname>Chomienne</surname><given-names>C.</given-names></name>
<name><surname>Dosquet</surname><given-names>C.</given-names></name>
<name><surname>Bellucci</surname><given-names>S.</given-names></name>
<name><surname>Valla</surname><given-names>D.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>The JAK2 46/1 haplotype in splanchnic vein thrombosis</article-title>. <source>Blood</source> <volume>117</volume>: <fpage>5777</fpage>–<lpage>5778</lpage>.</citation>
</ref>
<ref id="bibr72-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kralovics</surname><given-names>R.</given-names></name>
<name><surname>Buser</surname><given-names>A.</given-names></name>
<name><surname>Teo</surname><given-names>S.</given-names></name>
<name><surname>Coers</surname><given-names>J.</given-names></name>
<name><surname>Tichelli</surname><given-names>A.</given-names></name>
<name><surname>van der Maas</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2003a</year>) <article-title>Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders</article-title>. <source>Blood</source> <volume>102</volume>: <fpage>1869</fpage>–<lpage>1871</lpage>.</citation>
</ref>
<ref id="bibr73-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kralovics</surname><given-names>R.</given-names></name>
<name><surname>Passamonti</surname><given-names>F.</given-names></name>
<name><surname>Buser</surname><given-names>A.</given-names></name>
<name><surname>Teo</surname><given-names>S.</given-names></name>
<name><surname>Tiedt</surname><given-names>R.</given-names></name>
<name><surname>Passweg</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>A gain-of-function mutation of JAK2 in myeloproliferative disorders</article-title>. <source>N Engl J Med</source> <volume>352</volume>: <fpage>1779</fpage>–<lpage>1790</lpage>.</citation>
</ref>
<ref id="bibr74-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kralovics</surname><given-names>R.</given-names></name>
<name><surname>Stockton</surname><given-names>D.</given-names></name>
<name><surname>Prchal</surname><given-names>J.</given-names></name>
</person-group> (<year>2003b</year>) <article-title>Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease</article-title>. <source>Blood</source> <volume>102</volume>: <fpage>3793</fpage>–<lpage>3796</lpage>.</citation>
</ref>
<ref id="bibr75-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kristinsson</surname><given-names>S.</given-names></name>
<name><surname>Landgren</surname><given-names>O.</given-names></name>
<name><surname>Samuelsson</surname><given-names>J.</given-names></name>
<name><surname>Bjorkholm</surname><given-names>M.</given-names></name>
<name><surname>Goldin</surname><given-names>L.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Autoimmunity and the risk of myeloproliferative neoplasms</article-title>. <source>Haematologica</source> <volume>95</volume>: <fpage>1216</fpage>–<lpage>1220</lpage>.</citation>
</ref>
<ref id="bibr76-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lacout</surname><given-names>C.</given-names></name>
<name><surname>Pisani</surname><given-names>D.</given-names></name>
<name><surname>Tulliez</surname><given-names>M.</given-names></name>
<name><surname>Gachelin</surname><given-names>F.</given-names></name>
<name><surname>Vainchenker</surname><given-names>W.</given-names></name>
<name><surname>Villeval</surname><given-names>J.</given-names></name>
</person-group> (<year>2006</year>) <article-title>JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis</article-title>. <source>Blood</source> <volume>108</volume>: <fpage>1652</fpage>–<lpage>1660</lpage>.</citation>
</ref>
<ref id="bibr77-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ladroue</surname><given-names>C.</given-names></name>
<name><surname>Hoogewijs</surname><given-names>D.</given-names></name>
<name><surname>Gad</surname><given-names>S.</given-names></name>
<name><surname>Carcenac</surname><given-names>R.</given-names></name>
<name><surname>Storti</surname><given-names>F.</given-names></name>
<name><surname>Barrois</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Distinct deregulation of the hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia</article-title>. <source>Haematologica</source> <volume>97</volume>: <fpage>9</fpage>–<lpage>14</lpage>.</citation>
</ref>
<ref id="bibr78-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lambert</surname><given-names>J.</given-names></name>
<name><surname>Everington</surname><given-names>T.</given-names></name>
<name><surname>Linch</surname><given-names>D.</given-names></name>
<name><surname>Gale</surname><given-names>R.</given-names></name>
</person-group> (<year>2009</year>) <article-title>In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm</article-title>. <source>Blood</source> <volume>114</volume>: <fpage>3018</fpage>–<lpage>3023</lpage>.</citation>
</ref>
<ref id="bibr79-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Landgren</surname><given-names>O.</given-names></name>
<name><surname>Goldin</surname><given-names>L.</given-names></name>
<name><surname>Kristinsson</surname><given-names>S.</given-names></name>
<name><surname>Helgadottir</surname><given-names>E.</given-names></name>
<name><surname>Samuelsson</surname><given-names>J.</given-names></name>
<name><surname>Bjorkholm</surname><given-names>M.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden</article-title>. <source>Blood</source> <volume>112</volume>: <fpage>2199</fpage>–<lpage>2204</lpage>.</citation>
</ref>
<ref id="bibr80-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Langemeijer</surname><given-names>S.</given-names></name>
<name><surname>Kuiper</surname><given-names>R.</given-names></name>
<name><surname>Berends</surname><given-names>M.</given-names></name>
<name><surname>Knops</surname><given-names>R.</given-names></name>
<name><surname>Aslanyan</surname><given-names>M.</given-names></name>
<name><surname>Massop</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Acquired mutations in TET2 are common in myelodysplastic syndromes</article-title>. <source>Nat Genet</source> <volume>41</volume>: <fpage>838</fpage>–<lpage>842</lpage>.</citation>
</ref>
<ref id="bibr81-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lasho</surname><given-names>T.</given-names></name>
<name><surname>Pardanani</surname><given-names>A.</given-names></name>
<name><surname>McClure</surname><given-names>R.</given-names></name>
<name><surname>Mesa</surname><given-names>R.</given-names></name>
<name><surname>Levine</surname><given-names>R.</given-names></name>
<name><surname>Gary Gilliland</surname><given-names>D.</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time</article-title>. <source>Br J Haematol</source> <volume>135</volume>: <fpage>683</fpage>–<lpage>687</lpage>.</citation>
</ref>
<ref id="bibr82-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lasho</surname><given-names>T.</given-names></name>
<name><surname>Tefferi</surname><given-names>A.</given-names></name>
<name><surname>Pardanani</surname><given-names>A.</given-names></name>
<name><surname>Finke</surname><given-names>C.</given-names></name>
<name><surname>Fink</surname><given-names>S.</given-names></name>
<name><surname>Caron</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Differential distribution of CCDC26 glioma-risk alleles in myeloid malignancies with mutant IDH1 compared with their IDH2R140-mutated or IDH-unmutated counterparts</article-title>. <source>Leukemia</source> <volume>26</volume>: <fpage>1406</fpage>–<lpage>1407</lpage>.</citation>
</ref>
<ref id="bibr83-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lees</surname><given-names>C.</given-names></name>
<name><surname>Barrett</surname><given-names>J.</given-names></name>
<name><surname>Parkes</surname><given-names>M.</given-names></name>
<name><surname>Satsangi</surname><given-names>J.</given-names></name>
</person-group> (<year>2011</year>) <article-title>New IBD genetics: common pathways with other diseases</article-title>. <source>Gut</source> <volume>60</volume>: <fpage>1739</fpage>–<lpage>1753</lpage>.</citation>
</ref>
<ref id="bibr84-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Levine</surname><given-names>R.</given-names></name>
<name><surname>Wadleigh</surname><given-names>M.</given-names></name>
<name><surname>Cools</surname><given-names>J.</given-names></name>
<name><surname>Ebert</surname><given-names>B.</given-names></name>
<name><surname>Wernig</surname><given-names>G.</given-names></name>
<name><surname>Huntly</surname><given-names>B.</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis</article-title>. <source>Cancer Cell</source> <volume>7</volume>: <fpage>387</fpage>–<lpage>397</lpage>.</citation>
</ref>
<ref id="bibr85-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Li</surname><given-names>S.</given-names></name>
<name><surname>Kralovics</surname><given-names>R.</given-names></name>
<name><surname>De Libero</surname><given-names>G.</given-names></name>
<name><surname>Theocharides</surname><given-names>A.</given-names></name>
<name><surname>Gisslinger</surname><given-names>H.</given-names></name>
<name><surname>Skoda</surname><given-names>R.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations</article-title>. <source>Blood</source> <volume>111</volume>: <fpage>3863</fpage>–<lpage>3866</lpage>.</citation>
</ref>
<ref id="bibr86-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Liu</surname><given-names>K.</given-names></name>
<name><surname>Kralovics</surname><given-names>R.</given-names></name>
<name><surname>Rudzki</surname><given-names>Z.</given-names></name>
<name><surname>Grabowska</surname><given-names>B.</given-names></name>
<name><surname>Buser</surname><given-names>A.</given-names></name>
<name><surname>Olcaydu</surname><given-names>D.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>A de novo splice donor mutation in the thrombopoietin gene causes hereditary thrombocythemia in a Polish family</article-title>. <source>Haematologica</source> <volume>93</volume>: <fpage>706</fpage>–<lpage>714</lpage>.</citation>
</ref>
<ref id="bibr87-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Malcovati</surname><given-names>L.</given-names></name>
<name><surname>Papaemmanuil</surname><given-names>E.</given-names></name>
<name><surname>Bowen</surname><given-names>D.T.</given-names></name>
<name><surname>Boultwood</surname><given-names>J.</given-names></name>
<name><surname>Della Porta</surname><given-names>M.</given-names></name>
<name><surname>Pascutto</surname><given-names>C.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms</article-title>. <source>Blood</source> <volume>118</volume>: <fpage>6239</fpage>–<lpage>6246</lpage>.</citation>
</ref>
<ref id="bibr88-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Martini</surname><given-names>M.</given-names></name>
<name><surname>Teofili</surname><given-names>L.</given-names></name>
<name><surname>Cenci</surname><given-names>T.</given-names></name>
<name><surname>Giona</surname><given-names>F.</given-names></name>
<name><surname>Torti</surname><given-names>L.</given-names></name>
<name><surname>Rea</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>A novel heterozygous HIF2AM535I mutation reinforces the role of oxygen sensing pathway disturbances in the pathogenesis of familial erythrocytosis</article-title>. <source>Haematologica</source> <volume>93</volume>: <fpage>1068</fpage>–<lpage>1071</lpage>.</citation>
</ref>
<ref id="bibr89-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McMullin</surname><given-names>M.</given-names></name>
</person-group> (<year>2010</year>) <article-title>HIF pathway mutations and erythrocytosis</article-title>. <source>Exp Rev Hematol</source> <volume>3</volume>: <fpage>93</fpage>–<lpage>101</lpage>.</citation>
</ref>
<ref id="bibr90-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mead</surname><given-names>A.</given-names></name>
<name><surname>Rugless</surname><given-names>M.</given-names></name>
<name><surname>Jacobsen</surname><given-names>S.</given-names></name>
<name><surname>Schuh</surname><given-names>A.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Germline JAK2 mutation in a family with hereditary thrombocytosis</article-title>. <source>N Engl J Med</source> <volume>366</volume>: <fpage>967</fpage>–<lpage>969</lpage>.</citation>
</ref>
<ref id="bibr91-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meindl</surname><given-names>A.</given-names></name>
<name><surname>Hellebrand</surname><given-names>H.</given-names></name>
<name><surname>Wiek</surname><given-names>C.</given-names></name>
<name><surname>Erven</surname><given-names>V.</given-names></name>
<name><surname>Wappenschmidt</surname><given-names>B.</given-names></name>
<name><surname>Niederacher</surname><given-names>D.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene</article-title>. <source>Nat Genet</source> <volume>42</volume>: <fpage>410</fpage>–<lpage>414</lpage>.</citation>
</ref>
<ref id="bibr92-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Moliterno</surname><given-names>A.</given-names></name>
<name><surname>Williams</surname><given-names>D.</given-names></name>
<name><surname>Gutierrez-Alamillo</surname><given-names>L.</given-names></name>
<name><surname>Salvatori</surname><given-names>R.</given-names></name>
<name><surname>Ingersoll</surname><given-names>R.</given-names></name>
<name><surname>Spivak</surname><given-names>J.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Mpl Baltimore: a thrombopoietin receptor polymorphism associated with thrombocytosis</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>101</volume>: <fpage>11444</fpage>–<lpage>11447</lpage>.</citation>
</ref>
<ref id="bibr93-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nahajevszky</surname><given-names>S.</given-names></name>
<name><surname>Andrikovics</surname><given-names>H.</given-names></name>
<name><surname>Batai</surname><given-names>A.</given-names></name>
<name><surname>Adam</surname><given-names>E.</given-names></name>
<name><surname>Bors</surname><given-names>A.</given-names></name>
<name><surname>Csomor</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>The prognostic impact of germline 46/1 haplotype of Janus kinase 2 in cytogenetically normal acute myeloid leukemia</article-title>. <source>Haematologica</source> <volume>96</volume>: <fpage>1613</fpage>–<lpage>1618</lpage>.</citation>
</ref>
<ref id="bibr94-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Najean</surname><given-names>Y.</given-names></name>
<name><surname>Rain</surname><given-names>J.</given-names></name>
<name><surname>Billotey</surname><given-names>C.</given-names></name>
</person-group> (<year>1998</year>) <article-title>Epidemiological data in polycythaemia vera: a study of 842 cases</article-title>. <source>Hematol Cell Ther</source> <volume>40</volume>: <fpage>159</fpage>–<lpage>165</lpage>.</citation>
</ref>
<ref id="bibr95-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Newton-Cheh</surname><given-names>C.</given-names></name>
<name><surname>Johnson</surname><given-names>T.</given-names></name>
<name><surname>Gateva</surname><given-names>V.</given-names></name>
<name><surname>Tobin</surname><given-names>M.</given-names></name>
<name><surname>Bochud</surname><given-names>M.</given-names></name>
<name><surname>Coin</surname><given-names>L.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Genome-wide association study identifies eight loci associated with blood pressure</article-title>. <source>Nat Genet</source> <volume>41</volume>: <fpage>666</fpage>–<lpage>676</lpage>.</citation>
</ref>
<ref id="bibr96-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nielsen</surname><given-names>C.</given-names></name>
<name><surname>Birgens</surname><given-names>H.</given-names></name>
<name><surname>Nordestgaard</surname><given-names>B.</given-names></name>
<name><surname>Bojesen</surname><given-names>S.</given-names></name>
</person-group> (<year>2013</year>) <article-title>Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population</article-title>. <source>Br J Haematol</source> <volume>160</volume>: <fpage>70</fpage>–<lpage>79</lpage>.</citation>
</ref>
<ref id="bibr97-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nielsen</surname><given-names>C.</given-names></name>
<name><surname>Birgens</surname><given-names>H.</given-names></name>
<name><surname>Nordestgaard</surname><given-names>B.</given-names></name>
<name><surname>Kjaer</surname><given-names>L.</given-names></name>
<name><surname>Bojesen</surname><given-names>S.</given-names></name>
</person-group> (<year>2011</year>) <article-title>The JAK2 V617F somatic mutation, mortality and cancer risk in the general population</article-title>. <source>Haematologica</source> <volume>96</volume>: <fpage>450</fpage>–<lpage>453</lpage>.</citation>
</ref>
<ref id="bibr98-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nikoloski</surname><given-names>G.</given-names></name>
<name><surname>Langemeijer</surname><given-names>S.</given-names></name>
<name><surname>Kuiper</surname><given-names>R.</given-names></name>
<name><surname>Knops</surname><given-names>R.</given-names></name>
<name><surname>Massop</surname><given-names>M.</given-names></name>
<name><surname>Tonnissen</surname><given-names>E.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes</article-title>. <source>Nat Genet</source> <volume>42</volume>: <fpage>665</fpage>–<lpage>667</lpage>.</citation>
</ref>
<ref id="bibr99-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Oh</surname><given-names>S.</given-names></name>
<name><surname>Simonds</surname><given-names>E.</given-names></name>
<name><surname>Jones</surname><given-names>C.</given-names></name>
<name><surname>Hale</surname><given-names>M.</given-names></name>
<name><surname>Goltsev</surname><given-names>Y.</given-names></name>
<name><surname>Gibbs</surname><given-names>K.</given-names><suffix>Jr</suffix></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms</article-title>. <source>Blood</source> <volume>116</volume>: <fpage>988</fpage>–<lpage>992</lpage>.</citation>
</ref>
<ref id="bibr100-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ohyashiki</surname><given-names>J.</given-names></name>
<name><surname>Yoneta</surname><given-names>M.</given-names></name>
<name><surname>Hisatomi</surname><given-names>H.</given-names></name>
<name><surname>Iwabuchi</surname><given-names>T.</given-names></name>
<name><surname>Umezu</surname><given-names>T.</given-names></name>
<name><surname>Ohyashiki</surname><given-names>K.</given-names></name>
</person-group> (<year>2012</year>) <article-title>The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population</article-title>. <source>BMC Med Genet</source> <volume>13</volume>: <fpage>6</fpage>.</citation>
</ref>
<ref id="bibr101-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Olcaydu</surname><given-names>D.</given-names></name>
<name><surname>Harutyunyan</surname><given-names>A.</given-names></name>
<name><surname>Jager</surname><given-names>R.</given-names></name>
<name><surname>Berg</surname><given-names>T.</given-names></name>
<name><surname>Gisslinger</surname><given-names>B.</given-names></name>
<name><surname>Pabinger</surname><given-names>I.</given-names></name><etal/>
</person-group>. (<year>2009a</year>) <article-title>A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms</article-title>. <source>Nat Genet</source> <volume>41</volume>: <fpage>450</fpage>–<lpage>454</lpage>.</citation>
</ref>
<ref id="bibr102-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Olcaydu</surname><given-names>D.</given-names></name>
<name><surname>Skoda</surname><given-names>R.</given-names></name>
<name><surname>Looser</surname><given-names>R.</given-names></name>
<name><surname>Li</surname><given-names>S.</given-names></name>
<name><surname>Cazzola</surname><given-names>M.</given-names></name>
<name><surname>Pietra</surname><given-names>D.</given-names></name><etal/>
</person-group>. (<year>2009b</year>) <article-title>The ‘GGCC’ haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera</article-title>. <source>Leukemia</source> <volume>23</volume>: <fpage>1924</fpage>–<lpage>1926</lpage>.</citation>
</ref>
<ref id="bibr103-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Olcaydu</surname><given-names>D.</given-names></name>
<name><surname>Rumi</surname><given-names>E.</given-names></name>
<name><surname>Harutyunyan</surname><given-names>A.</given-names></name>
<name><surname>Passamonti</surname><given-names>F.</given-names></name>
<name><surname>Pietra</surname><given-names>D.</given-names></name>
<name><surname>Pascutto</surname><given-names>C.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms</article-title>. <source>Haematologica</source> <volume>96</volume>: <fpage>367</fpage>–<lpage>374</lpage>.</citation>
</ref>
<ref id="bibr104-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pardanani</surname><given-names>A.</given-names></name>
<name><surname>Fridley</surname><given-names>B.</given-names></name>
<name><surname>Lasho</surname><given-names>T.</given-names></name>
<name><surname>Gilliland</surname><given-names>D.</given-names></name>
<name><surname>Tefferi</surname><given-names>A.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders</article-title>. <source>Blood</source> <volume>111</volume>: <fpage>2785</fpage>–<lpage>2789</lpage>.</citation>
</ref>
<ref id="bibr105-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pardanani</surname><given-names>A.</given-names></name>
<name><surname>Lasho</surname><given-names>T.</given-names></name>
<name><surname>Finke</surname><given-names>C.</given-names></name>
<name><surname>Oh</surname><given-names>S.</given-names></name>
<name><surname>Gotlib</surname><given-names>J.</given-names></name>
<name><surname>Tefferi</surname><given-names>A.</given-names></name>
</person-group> (<year>2010a</year>) <article-title>LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations</article-title>. <source>Leukemia</source> <volume>24</volume>: <fpage>1713</fpage>–<lpage>1718</lpage>.</citation>
</ref>
<ref id="bibr106-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pardanani</surname><given-names>A.</given-names></name>
<name><surname>Lasho</surname><given-names>T.</given-names></name>
<name><surname>Finke</surname><given-names>C.</given-names></name>
<name><surname>Gangat</surname><given-names>N.</given-names></name>
<name><surname>Wolanskyj</surname><given-names>A.</given-names></name>
<name><surname>Hanson</surname><given-names>C.</given-names></name><etal/>
</person-group>. (<year>2010b</year>) <article-title>The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients</article-title>. <source>Leukemia</source> <volume>24</volume>: <fpage>110</fpage>–<lpage>114</lpage>.</citation>
</ref>
<ref id="bibr107-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pastore</surname><given-names>Y.</given-names></name>
<name><surname>Jelinek</surname><given-names>J.</given-names></name>
<name><surname>Ang</surname><given-names>S.</given-names></name>
<name><surname>Guan</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>E.</given-names></name>
<name><surname>Jedlickova</surname><given-names>K.</given-names></name><etal/>
</person-group>. (<year>2003</year>) <article-title>Mutations in the VHL gene in sporadic apparently congenital polycythemia</article-title>. <source>Blood</source> <volume>101</volume>: <fpage>1591</fpage>–<lpage>1595</lpage>.</citation>
</ref>
<ref id="bibr108-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Percy</surname><given-names>M.</given-names></name>
<name><surname>Beer</surname><given-names>P.</given-names></name>
<name><surname>Campbell</surname><given-names>G.</given-names></name>
<name><surname>Dekker</surname><given-names>A.</given-names></name>
<name><surname>Green</surname><given-names>A.</given-names></name>
<name><surname>Oscier</surname><given-names>D.</given-names></name><etal/>
</person-group>. (<year>2008a</year>) <article-title>Novel exon 12 mutations in the HIF2A gene associated with erythrocytosis</article-title>. <source>Blood</source> <volume>111</volume>: <fpage>5400</fpage>–<lpage>5402</lpage>.</citation>
</ref>
<ref id="bibr109-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Percy</surname><given-names>M.</given-names></name>
<name><surname>Furlow</surname><given-names>P.</given-names></name>
<name><surname>Beer</surname><given-names>P.</given-names></name>
<name><surname>Lappin</surname><given-names>T.</given-names></name>
<name><surname>McMullin</surname><given-names>M.</given-names></name>
<name><surname>Lee</surname><given-names>F.</given-names></name>
</person-group> (<year>2007a</year>) <article-title>A novel erythrocytosis-associated PHD2 mutation suggests the location of a HIF binding groove</article-title>. <source>Blood</source> <volume>110</volume>: <fpage>2193</fpage>–<lpage>2196</lpage>.</citation>
</ref>
<ref id="bibr110-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Percy</surname><given-names>M.</given-names></name>
<name><surname>Furlow</surname><given-names>P.</given-names></name>
<name><surname>Lucas</surname><given-names>G.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Lappin</surname><given-names>T.</given-names></name>
<name><surname>McMullin</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>2008b</year>) <article-title>A gain-of-function mutation in the HIF2A gene in familial erythrocytosis</article-title>. <source>N Engl J Med</source> <volume>358</volume>: <fpage>162</fpage>–<lpage>168</lpage>.</citation>
</ref>
<ref id="bibr111-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Percy</surname><given-names>M.</given-names></name>
<name><surname>Scott</surname><given-names>L.</given-names></name>
<name><surname>Erber</surname><given-names>W.</given-names></name>
<name><surname>Harrison</surname><given-names>C.</given-names></name>
<name><surname>Reilly</surname><given-names>J.</given-names></name>
<name><surname>Jones</surname><given-names>F.</given-names></name><etal/>
</person-group>. (<year>2007b</year>) <article-title>The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels</article-title>. <source>Haematologica</source> <volume>92</volume>: <fpage>1607</fpage>–<lpage>1614</lpage>.</citation>
</ref>
<ref id="bibr112-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Percy</surname><given-names>M.</given-names></name>
<name><surname>Zhao</surname><given-names>Q.</given-names></name>
<name><surname>Flores</surname><given-names>A.</given-names></name>
<name><surname>Harrison</surname><given-names>C.</given-names></name>
<name><surname>Lappin</surname><given-names>T.</given-names></name>
<name><surname>Maxwell</surname><given-names>P.</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>103</volume>: <fpage>654</fpage>–<lpage>659</lpage>.</citation>
</ref>
<ref id="bibr113-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Piazza</surname><given-names>R.</given-names></name>
<name><surname>Valletta</surname><given-names>S.</given-names></name>
<name><surname>Winkelmann</surname><given-names>N.</given-names></name>
<name><surname>Redaelli</surname><given-names>S.</given-names></name>
<name><surname>Spinelli</surname><given-names>R.</given-names></name>
<name><surname>Pirola</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Recurrent SETBP1 mutations in atypical chronic myeloid leukemia</article-title>. <source>Nat Genet</source> <volume>45</volume>: <fpage>18</fpage>–<lpage>24</lpage>.</citation>
</ref>
<ref id="bibr114-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pietra</surname><given-names>D.</given-names></name>
<name><surname>Casetti</surname><given-names>I.</given-names></name>
<name><surname>Da Vià</surname><given-names>M.</given-names></name>
<name><surname>Elena</surname><given-names>C.</given-names></name>
<name><surname>Milanesi</surname><given-names>C.</given-names></name>
<name><surname>Rumi</surname><given-names>E.</given-names></name>
</person-group> (<year>2012</year>) <article-title>JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms</article-title>. <source>Am J Hematol</source> <volume>87</volume>: <fpage>746</fpage>–<lpage>747</lpage>.</citation>
</ref>
<ref id="bibr115-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pikman</surname><given-names>Y.</given-names></name>
<name><surname>Lee</surname><given-names>B.</given-names></name>
<name><surname>Mercher</surname><given-names>T.</given-names></name>
<name><surname>McDowell</surname><given-names>E.</given-names></name>
<name><surname>Ebert</surname><given-names>B.</given-names></name>
<name><surname>Gozo</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title><italic>MPL</italic> W515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia</article-title>. <source>PLoS Med</source> <volume>3</volume>(<issue>7</issue>): <fpage>e270</fpage>.</citation>
</ref>
<ref id="bibr116-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Plo</surname><given-names>I.</given-names></name>
<name><surname>Nakatake</surname><given-names>M.</given-names></name>
<name><surname>Malivert</surname><given-names>L.</given-names></name>
<name><surname>de Villartay</surname><given-names>J.</given-names></name>
<name><surname>Giraudier</surname><given-names>S.</given-names></name>
<name><surname>Villeval</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders</article-title>. <source>Blood</source> <volume>112</volume>: <fpage>1402</fpage>–<lpage>1412</lpage>.</citation>
</ref>
<ref id="bibr117-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Poletto</surname><given-names>V.</given-names></name>
<name><surname>Rosti</surname><given-names>V.</given-names></name>
<name><surname>Villani</surname><given-names>L.</given-names></name>
<name><surname>Catarsi</surname><given-names>P.</given-names></name>
<name><surname>Carolei</surname><given-names>A.</given-names></name>
<name><surname>Campanelli</surname><given-names>R.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>A3669G polymorphism of glucocorticoid receptor is a susceptibility allele for primary myelofibrosis and contributes to phenotypic diversity and blast transformation</article-title>. <source>Blood</source> <volume>120</volume>: <fpage>3112</fpage>–<lpage>3117</lpage>.</citation>
</ref>
<ref id="bibr118-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Prchal</surname><given-names>J.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Polycythemia vera and other primary polycythemias</article-title>. <source>Curr Opin Hematol</source> <volume>12</volume>: <fpage>112</fpage>–<lpage>116</lpage>.</citation>
</ref>
<ref id="bibr119-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Prchal</surname><given-names>J.</given-names></name>
<name><surname>Crist</surname><given-names>W.</given-names></name>
<name><surname>Goldwasser</surname><given-names>E.</given-names></name>
<name><surname>Perrine</surname><given-names>G.</given-names></name>
<name><surname>Prchal</surname><given-names>J.</given-names></name>
</person-group> (<year>1985</year>) <article-title>Autosomal dominant polycythemia</article-title>. <source>Blood</source> <volume>66</volume>: <fpage>1208</fpage>–<lpage>1214</lpage>.</citation>
</ref>
<ref id="bibr120-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rondeau</surname><given-names>E.</given-names></name>
<name><surname>Solal-Celigny</surname><given-names>P.</given-names></name>
<name><surname>Dhermy</surname><given-names>D.</given-names></name>
<name><surname>Vroclans</surname><given-names>M.</given-names></name>
<name><surname>Brousse</surname><given-names>N.</given-names></name>
<name><surname>Bernard</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>1983</year>) <article-title>Immune disorders in agnogenic myeloid metaplasia: relations to myelofibrosis</article-title>. <source>Br J Haematol</source> <volume>53</volume>: <fpage>467</fpage>–<lpage>475</lpage>.</citation>
</ref>
<ref id="bibr121-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rumi</surname><given-names>E.</given-names></name>
<name><surname>Harutyunyan</surname><given-names>A.</given-names></name>
<name><surname>Pietra</surname><given-names>D.</given-names></name>
</person-group> (<year>2012</year>) <article-title>A novel germline JAK2 mutation in familial thrombocytosis</article-title>. <source>Haematologica</source> <volume>97</volume>(<supplement>Suppl. 1</supplement>): <fpage>244</fpage>.</citation>
</ref>
<ref id="bibr122-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rumi</surname><given-names>E.</given-names></name>
<name><surname>Passamonti</surname><given-names>F.</given-names></name>
<name><surname>Della Porta</surname><given-names>M.</given-names></name>
<name><surname>Elena</surname><given-names>C.</given-names></name>
<name><surname>Arcaini</surname><given-names>L.</given-names></name>
<name><surname>Vanelli</surname><given-names>L.</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation</article-title>. <source>J Clin Oncol</source> <volume>25</volume>: <fpage>5630</fpage>–<lpage>5635</lpage>.</citation>
</ref>
<ref id="bibr123-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rumi</surname><given-names>E.</given-names></name>
<name><surname>Passamonti</surname><given-names>F.</given-names></name>
<name><surname>Elena</surname><given-names>C.</given-names></name>
<name><surname>Pietra</surname><given-names>D.</given-names></name>
<name><surname>Arcaini</surname><given-names>L.</given-names></name>
<name><surname>Astori</surname><given-names>C.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients</article-title>. <source>Haematologica</source> <volume>96</volume>: <fpage>454</fpage>–<lpage>458</lpage>.</citation>
</ref>
<ref id="bibr124-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rumi</surname><given-names>E.</given-names></name>
<name><surname>Passamonti</surname><given-names>F.</given-names></name>
<name><surname>Pietra</surname><given-names>D.</given-names></name>
<name><surname>Della Porta</surname><given-names>M.</given-names></name>
<name><surname>Arcaini</surname><given-names>L.</given-names></name>
<name><surname>Boggi</surname><given-names>S.</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders</article-title>. <source>Cancer</source> <volume>107</volume>: <fpage>2206</fpage>–<lpage>2211</lpage>.</citation>
</ref>
<ref id="bibr125-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Saint-Martin</surname><given-names>C.</given-names></name>
<name><surname>Leroy</surname><given-names>G.</given-names></name>
<name><surname>Delhommeau</surname><given-names>F.</given-names></name>
<name><surname>Panelatti</surname><given-names>G.</given-names></name>
<name><surname>Dupont</surname><given-names>S.</given-names></name>
<name><surname>James</surname><given-names>C.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms</article-title>. <source>Blood</source> <volume>114</volume>: <fpage>1628</fpage>–<lpage>1632</lpage>.</citation>
</ref>
<ref id="bibr126-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sanada</surname><given-names>M.</given-names></name>
<name><surname>Suzuki</surname><given-names>T.</given-names></name>
<name><surname>Shih</surname><given-names>L.</given-names></name>
<name><surname>Otsu</surname><given-names>M.</given-names></name>
<name><surname>Kato</surname><given-names>M.</given-names></name>
<name><surname>Yamazaki</surname><given-names>S.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms</article-title>. <source>Nature</source> <volume>460</volume>: <fpage>904</fpage>–<lpage>908</lpage>.</citation>
</ref>
<ref id="bibr127-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schaub</surname><given-names>F.</given-names></name>
<name><surname>Looser</surname><given-names>R.</given-names></name>
<name><surname>Li</surname><given-names>S.</given-names></name>
<name><surname>Hao-Shen</surname><given-names>H.</given-names></name>
<name><surname>Lehmann</surname><given-names>T.</given-names></name>
<name><surname>Tichelli</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms</article-title>. <source>Blood</source> <volume>115</volume>: <fpage>2003</fpage>–<lpage>2007</lpage>.</citation>
</ref>
<ref id="bibr128-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Score</surname><given-names>J.</given-names></name>
<name><surname>Cross</surname><given-names>N.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Acquired uniparental disomy in myeloproliferative neoplasms</article-title>. <source>Hematol Oncol Clin North Am</source> <volume>26</volume>: <fpage>981</fpage>–<lpage>991</lpage>.</citation>
</ref>
<ref id="bibr129-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Scott</surname><given-names>L.</given-names></name>
</person-group> (<year>2011</year>) <article-title>The JAK2 exon 12 mutations: a comprehensive review</article-title>. <source>Am J Hematol</source> <volume>86</volume>: <fpage>668</fpage>–<lpage>676</lpage>.</citation>
</ref>
<ref id="bibr130-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Scott</surname><given-names>L.</given-names></name>
<name><surname>Scott</surname><given-names>M.</given-names></name>
<name><surname>Campbell</surname><given-names>P.</given-names></name>
<name><surname>Green</surname><given-names>A.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia</article-title>. <source>Blood</source> <volume>108</volume>: <fpage>2435</fpage>–<lpage>2437</lpage>.</citation>
</ref>
<ref id="bibr131-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Scott</surname><given-names>L.</given-names></name>
<name><surname>Tong</surname><given-names>W.</given-names></name>
<name><surname>Levine</surname><given-names>R.</given-names></name>
<name><surname>Scott</surname><given-names>M.</given-names></name>
<name><surname>Beer</surname><given-names>P.</given-names></name>
<name><surname>Stratton</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis</article-title>. <source>N Engl J Med</source> <volume>356</volume>: <fpage>459</fpage>–<lpage>468</lpage>.</citation>
</ref>
<ref id="bibr132-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sergeyeva</surname><given-names>A.</given-names></name>
<name><surname>Gordeuk</surname><given-names>V.</given-names></name>
<name><surname>Tokarev</surname><given-names>Y.</given-names></name>
<name><surname>Sokol</surname><given-names>L.</given-names></name>
<name><surname>Prchal</surname><given-names>J.</given-names></name>
<name><surname>Prchal</surname><given-names>J.</given-names></name>
</person-group> (<year>1997</year>) <article-title>Congenital polycythemia in Chuvashia</article-title>. <source>Blood</source> <volume>89</volume>: <fpage>2148</fpage>–<lpage>2154</lpage>.</citation>
</ref>
<ref id="bibr133-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Skoda</surname><given-names>R.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Hereditary myeloproliferative disorders</article-title>. <source>Haematologica</source> <volume>95</volume>: <fpage>6</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr134-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Smalberg</surname><given-names>J.</given-names></name>
<name><surname>Koehler</surname><given-names>E.</given-names></name>
<name><surname>Darwish Murad</surname><given-names>S.</given-names></name>
<name><surname>Plessier</surname><given-names>A.</given-names></name>
<name><surname>Seijo</surname><given-names>S.</given-names></name>
<name><surname>Trebicka</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>The JAK2 46/1 haplotype in Budd-Chiari syndrome and portal vein thrombosis</article-title>. <source>Blood</source> <volume>117</volume>: <fpage>3968</fpage>–<lpage>3973</lpage>.</citation>
</ref>
<ref id="bibr135-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stegelmann</surname><given-names>F.</given-names></name>
<name><surname>Bullinger</surname><given-names>L.</given-names></name>
<name><surname>Schlenk</surname><given-names>R.</given-names></name>
<name><surname>Paschka</surname><given-names>P.</given-names></name>
<name><surname>Griesshammer</surname><given-names>M.</given-names></name>
<name><surname>Blersch</surname><given-names>C.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>DNMT3A mutations in myeloproliferative neoplasms</article-title>. <source>Leukemia</source> <volume>25</volume>: <fpage>1217</fpage>–<lpage>1219</lpage>.</citation>
</ref>
<ref id="bibr136-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tefferi</surname><given-names>A.</given-names></name>
<name><surname>Lasho</surname><given-names>T.</given-names></name>
<name><surname>Abdel-Wahab</surname><given-names>O.</given-names></name>
<name><surname>Guglielmelli</surname><given-names>P.</given-names></name>
<name><surname>Patel</surname><given-names>J.</given-names></name>
<name><surname>Caramazza</surname><given-names>D.</given-names></name><etal/>
</person-group>. (<year>2010a</year>) <article-title>IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis</article-title>. <source>Leukemia</source> <volume>24</volume>: <fpage>1302</fpage>–<lpage>1309</lpage>.</citation>
</ref>
<ref id="bibr137-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tefferi</surname><given-names>A.</given-names></name>
<name><surname>Lasho</surname><given-names>T.</given-names></name>
<name><surname>Patnaik</surname><given-names>M.</given-names></name>
<name><surname>Finke</surname><given-names>C.</given-names></name>
<name><surname>Hussein</surname><given-names>K.</given-names></name>
<name><surname>Hogan</surname><given-names>W.</given-names></name><etal/>
</person-group>. (<year>2010b</year>) <article-title>JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival</article-title>. <source>Leukemia</source> <volume>24</volume>: <fpage>105</fpage>–<lpage>109</lpage>.</citation>
</ref>
<ref id="bibr138-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tefferi</surname><given-names>A.</given-names></name>
<name><surname>Pardanani</surname><given-names>A.</given-names></name>
<name><surname>Lim</surname><given-names>K.</given-names></name>
<name><surname>Abdel-Wahab</surname><given-names>O.</given-names></name>
<name><surname>Lasho</surname><given-names>T.</given-names></name>
<name><surname>Patel</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis</article-title>. <source>Leukemia</source> <volume>23</volume>: <fpage>905</fpage>–<lpage>911</lpage>.</citation>
</ref>
<ref id="bibr139-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tefferi</surname><given-names>A.</given-names></name>
<name><surname>Vardiman</surname><given-names>J.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms</article-title>. <source>Leukemia</source> <volume>22</volume>: <fpage>14</fpage>–<lpage>22</lpage>.</citation>
</ref>
<ref id="bibr140-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Teofili</surname><given-names>L.</given-names></name>
<name><surname>Giona</surname><given-names>F.</given-names></name>
<name><surname>Torti</surname><given-names>L.</given-names></name>
<name><surname>Cenci</surname><given-names>T.</given-names></name>
<name><surname>Ricerca</surname><given-names>B.</given-names></name>
<name><surname>Rumi</surname><given-names>C.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis</article-title>. <source>Haematologica</source> <volume>95</volume>: <fpage>65</fpage>–<lpage>70</lpage>.</citation>
</ref>
<ref id="bibr141-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tiedt</surname><given-names>R.</given-names></name>
<name><surname>Hao-Shen</surname><given-names>H.</given-names></name>
<name><surname>Sobas</surname><given-names>M.</given-names></name>
<name><surname>Looser</surname><given-names>R.</given-names></name>
<name><surname>Dirnhofer</surname><given-names>S.</given-names></name>
<name><surname>Schwaller</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice</article-title>. <source>Blood</source> <volume>111</volume>: <fpage>3931</fpage>–<lpage>3940</lpage>.</citation>
</ref>
<ref id="bibr142-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>van der Harst</surname><given-names>P.</given-names></name>
<name><surname>Zhang</surname><given-names>W.</given-names></name>
<name><surname>Mateo Leach</surname><given-names>I.</given-names></name>
<name><surname>Rendon</surname><given-names>A.</given-names></name>
<name><surname>Verweij</surname><given-names>N.</given-names></name>
<name><surname>Sehmi</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Seventy-five genetic loci influencing the human red blood cell</article-title>. <source>Nature</source> <volume>492</volume>: <fpage>369</fpage>–<lpage>375</lpage>.</citation>
</ref>
<ref id="bibr143-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vannucchi</surname><given-names>A.</given-names></name>
<name><surname>Masala</surname><given-names>G.</given-names></name>
<name><surname>Antonioli</surname><given-names>E.</given-names></name>
<name><surname>Chiara Susini</surname><given-names>M.</given-names></name>
<name><surname>Guglielmelli</surname><given-names>P.</given-names></name>
<name><surname>Pieri</surname><given-names>L.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source> <volume>18</volume>: <fpage>2068</fpage>–<lpage>2073</lpage>.</citation>
</ref>
<ref id="bibr144-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vardiman</surname><given-names>J.</given-names></name>
<name><surname>Harris</surname><given-names>N.</given-names></name>
<name><surname>Brunning</surname><given-names>R.</given-names></name>
</person-group> (<year>2002</year>) <article-title>The World Health Organization (WHO) classification of the myeloid neoplasms</article-title>. <source>Blood</source> <volume>100</volume>: <fpage>2292</fpage>–<lpage>2302</lpage>.</citation>
</ref>
<ref id="bibr145-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Varricchio</surname><given-names>L.</given-names></name>
<name><surname>Masselli</surname><given-names>E.</given-names></name>
<name><surname>Alfani</surname><given-names>E.</given-names></name>
<name><surname>Battistini</surname><given-names>A.</given-names></name>
<name><surname>Migliaccio</surname><given-names>G.</given-names></name>
<name><surname>Vannucchi</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>The dominant negative beta isoform of the glucocorticoid receptor is uniquely expressed in erythroid cells expanded from polycythemia vera patients</article-title>. <source>Blood</source> <volume>118</volume>: <fpage>425</fpage>–<lpage>436</lpage>.</citation>
</ref>
<ref id="bibr146-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vilaine</surname><given-names>M.</given-names></name>
<name><surname>Gourain</surname><given-names>V.</given-names></name>
<name><surname>Cleyrat</surname><given-names>C.</given-names></name>
<name><surname>Feron</surname><given-names>D.</given-names></name>
<name><surname>Girodon</surname><given-names>F.</given-names></name>
<name><surname>Morineau</surname><given-names>N.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Germline MPLW515R mutation in a family with isolated thrombocytosis</article-title>. <source>ASH Annual Meeting Abstracts</source> <volume>120</volume>: <fpage>1764</fpage>.</citation>
</ref>
<ref id="bibr147-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Xu</surname><given-names>Z.</given-names></name>
<name><surname>Liu</surname><given-names>L.</given-names></name>
<name><surname>Gale</surname><given-names>R.</given-names></name>
<name><surname>Cross</surname><given-names>N.</given-names></name>
<name><surname>Jones</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2013</year>) <article-title>JAK2V617F allele burden, JAK2 46/1 haplotype and clinical features of Chinese with myeloproliferative neoplasms</article-title>. <source>Leukemia</source>, in press.</citation>
</ref>
<ref id="bibr148-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wernig</surname><given-names>G.</given-names></name>
<name><surname>Mercher</surname><given-names>T.</given-names></name>
<name><surname>Okabe</surname><given-names>R.</given-names></name>
<name><surname>Levine</surname><given-names>R.</given-names></name>
<name><surname>Lee</surname><given-names>B.</given-names></name>
<name><surname>Gilliland</surname><given-names>D.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model</article-title>. <source>Blood</source> <volume>107</volume>: <fpage>4274</fpage>–<lpage>4281</lpage>.</citation>
</ref>
<ref id="bibr149-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wiestner</surname><given-names>A.</given-names></name>
<name><surname>Schlemper</surname><given-names>R.</given-names></name>
<name><surname>van der Maas</surname><given-names>A.</given-names></name>
<name><surname>Skoda</surname><given-names>R.</given-names></name>
</person-group> (<year>1998</year>) <article-title>An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia</article-title>. <source>Nat Genet</source> <volume>18</volume>: <fpage>49</fpage>–<lpage>52</lpage>.</citation>
</ref>
<ref id="bibr150-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zaleskas</surname><given-names>V.</given-names></name>
<name><surname>Krause</surname><given-names>D.</given-names></name>
<name><surname>Lazarides</surname><given-names>K.</given-names></name>
<name><surname>Patel</surname><given-names>N.</given-names></name>
<name><surname>Hu</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>S.</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F</article-title>. <source>PLoS One</source> <volume>1</volume>: <fpage>e18</fpage>.</citation>
</ref>
<ref id="bibr151-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>S.</given-names></name>
<name><surname>Rampal</surname><given-names>R.</given-names></name>
<name><surname>Manshouri</surname><given-names>T.</given-names></name>
<name><surname>Patel</surname><given-names>J.</given-names></name>
<name><surname>Mensah</surname><given-names>N.</given-names></name>
<name><surname>Kayserian</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2012a</year>) <article-title>Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome</article-title>. <source>Blood</source> <volume>119</volume>: <fpage>4480</fpage>–<lpage>4485</lpage>.</citation>
</ref>
<ref id="bibr152-2040620713489144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Hu</surname><given-names>T.</given-names></name>
<name><surname>Wu</surname><given-names>Z.</given-names></name>
<name><surname>Kang</surname><given-names>Z.</given-names></name>
<name><surname>Liu</surname><given-names>W.</given-names></name>
<name><surname>Guan</surname><given-names>M.</given-names></name>
</person-group> (<year>2012b</year>) <article-title>The JAK2 46/1 haplotype is a risk factor for myeloproliferative neoplasms in Chinese patients</article-title>. <source>Int J Hematol</source> <volume>96</volume>: <fpage>611</fpage>–<lpage>616</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>